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CHAPTER I 
 
INTRODUCTION 
 
Human head and neck carcinoma statistics 
Worldwide, head and neck carcinoma is the sixth leading cancer by incidence and 
is responsible for greater than 550,000 new cases and 300,000 deaths each year (Jemal et 
al., 2011).  Within the United States, head and neck carcinoma accounts for three percent 
of all malignancies, and this year alone, it is estimated that approximately 60,000 new 
patients will develop head and neck carcinoma and an estimated 12,300 patients will die 
from the disease (NCI, 2016).  
While ninety percent of all head and neck cancers are squamous cell carcinomas 
(HNSCC), the disease can be further subcategorized based on the region of origin. There 
are four major subcategories: 1) the oral cavity, which includes the anterior tongue, lips, 
roof and floor of mouth (bucosa); 2) the oropharynx, which includes the base of tongue, 
pharynx, surrounding area; 3) the nasopharynx, which includes all of the nasal sinuses; 
and 4) the larynx (see Figure 1.1).  The focus of this body of work is on head and neck 
carcinomas originating from the oral cavity and oropharyngeal subcategories, as the 
majority (approximately seventy-seven percent) of all head and neck carcinomas are 
derived from those regions (NCI, 2016). Oral and oropharyngeal cancer diagnoses are 
twice as high in men as women, with an estimated 32,670 men and 13,110 women being 
diagnosed this year (NCI, 2016). Approximately seventy percent (6,010 men and 2,640 
women) of patients that die each year from HNSCC will have disease derived from the  
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Figure 1.1 Head and neck cancer regions.  Shown are the different regions of 
the head and neck from which HNSCC can originate. Carcinomas originating from 
the oral cavity and the oropharynx (red boxes) are explored in this dissertation. 
Image retrieved from the National Cancer Institute  
(http://www.cancer.gov/types/head-and-neck/) 
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oral cavity and oropharynx (NCI, 2016). 
 
The highly variable survival rates of oral and oropharyngeal carcinomas depend 
on a variety of factors.  These factors include the stage and metastatic spread of the 
particular tumor at the time of diagnosis and the underlying mechanism of tumor 
promotion.  Overall, five-year and ten-year survival rates of patients with oral cavity and 
oropharyngeal cancer remain relatively poor at sixty-three percent, and fifty-one percent, 
respectively (NCI, 2016).  Importantly, there are improved survival rates for patients that 
have been diagnosed at an early stage in their disease. For example, five-year survival 
rates can be as high as eighty-three percent in patients diagnosed with Stage I oral or 
oropharyngeal cancer, however, these survival rates decrease as the stage at time of 
diagnosis increases (NCI, 2016).  The average survival rate of patients with cancer that 
has invaded local or surrounding tissues or that has metastasized to regional lymph nodes 
is as low as sixty-one percent survival (NCI, 2016).  In the rare case that the oral or 
oropharyngeal cancer has metastasized to a distant organ, survival rates decrease even 
further to thirty-seven percent survival (NCI, 2016). 
 
Risk Factors 
Tobacco, alcohol, and betel quid 
There are several different environmental risk factors that lead to the development 
and promotion of oral cavity and oropharyngeal carcinoma.  The use of tobacco products, 
including cigarettes, cigars, pipes, chewing tobacco, and snuff, is the single largest risk 
factor for HNSCC (NCI, 2016).  The use of tobacco products is so significant to the 
development of this disease that it is linked to eighty-five percent of all HNSCC (NCI, 
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2016).  Chewing tobacco, in particular, is associated with a 50% increase in the risk of 
developing HNSCC within the oral cavity (specifically in the cheeks, gums, inner lip) 
that has come in direct contact with the tobacco product (NCI, 2016).  
Other chewing products such as Betel Quid (BQ) have been shown to be risk 
factors for increased development of oral cavity, oropharyngeal, and esophageal 
carcinomas as a result of predominant use in southeast Asia, Taiwan and Papua New 
Guinea (reviewed in Nair et al., 2004).  BQ, a mixture of areca nut (Areca catechu), 
catechu (Acacia catechu) and slaked lime (calcium oxide and calcium hydroxide) 
wrapped in a betel leaf (Piper betel), promotes cancerous transformations that lead to 
HNSCC, and has also been shown to have an increased negative effect when used 
together tobacco products (reviewed in Nair et al., 2004).    
Alcohol use that is described as both frequent and heavy is another serious risk 
factor that leads to the development of oral cavity and oropharyngeal carcinomas.  
Similar to the combinatorial effect of using BQ and tobacco, alcohol and tobacco use also 
have a synergistic effect on the risk of developing the disease and are frequent 
comorbidities within HNSCC patients.  
 
Genetic mutations 
Genetic mutations are also risk factors that predispose patients to a higher 
probability of developing head and neck squamous cell carcinoma.  The most common 
example are mutations in the tumor suppressor TP53 that promote cancer by altering the 
regulation of the cell cycle and ultimately immortalizing otherwise normal epithelial cells 
(Leemans et al., 2011). In addition to mutations in TP53, proteins associated with tumor 
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survival (PIK3CA-AKT1-MTOR-PTEN, EGFR and MET pathways), tumor proliferation 
(p16, RB, MET, CCND1, CDKN2A/CDKN2B), and tumor differentiation (NOTCH1) 
have also been implicated as risk factors for malignant transformation (Agrawal et al., 
2011; Lechner et al., 2013; Marur and Forastiere, 2016).  Other genetic predispositions 
include inability to metabolize carcinogens and impaired ability to repair damaged DNA 
(Scully, 2000).  Genetic mutations resulting in the development and progression of 
HNSCCs also reduce the sensitivity of those tumors to chemoradiation and ultimately 
more difficult to treat.  
 
Infection with oncogenic human papillomavirus  
Human papillomavirus (HPV), a sexually transmitted virus, has been linked to the 
development of carcinomas in cutaneous squamous epithelium located in the cervix, 
anogenital region, and oropharyngeal region (reviewed in Marur and Forastiere, 2016; 
NCI, 2016).  If viral infections are not cleared by the body’s immune response, the viral 
DNA can integrate into the human genome.  The resulting expression of E6 and E7 viral 
proteins target and alter the normal functions of tumor suppressors TP53 or RB that result 
in uncontrolled cell growth and cell transformation (Vidal et al., 2008).  Disruption of RB 
function by viral protein E7 results in the expression of p16 INK4A, and is used as the 
clinical marker to identify HPV-positive tissues (Zhang et al., 1999).   HPV-positive head 
and neck cancers can be further subcategorized due to the unique genetic and phenotypic 
characteristics of the resulting tumors.  There are several oncogenic subtypes of HPV, 
HPV-16, HPV-18, HPV-31, and HPV-33, all of which increase the risk of malignant 
transformation in transformed cells (Marur and Forastiere, 2016).   Although many HPV 
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strains exist, genotyping has revealed HPV-16 as the highest-risk strain that has been 
specifically identified as a causative agent in oropharyngeal cancer (NCI, 2016).  Many 
patients that present with oropharyngeal cancer do not have the other traditional risk 
factors (frequent tobacco and alcohol use), which further implicate the role of the virus in 
the promotion of the disease.  Importantly, rates of incidence for oropharyngeal cancer 
are increasing, an occurrence that is attributed to the overall increase in human 
papillomavirus (HPV) infections (Leemas et al., 2011; NCI, 2016).   
 
Pathology, classification, and treatment 
 Oral cavity and oropharyngeal cancers invade primarily via local invasion of the 
same tissue, and if left untreated, may metastasize to regional lymph nodes. The tumors 
and extent of the disease have traditionally been classified using the ‘TNM’ method 
where T describes the size and location of the primary tumor, N describes the number of 
lymph nodes to which the primary cancer has spread, and the M describes the number of 
other metastases (Leemans et al., 2011; NCI, 2016). Together, these TNM classifications 
determine the stage of the cancer, ranging from Stage 0 to Stage IV, and are then used to 
direct or develop a treatment plan.  More recently, HPV-status of the tumor has become 
an important prognostic factor in directing therapeutic options (Leemans et al., 2011).  
Standard treatment plans begin with surgical resection of the primary tumor, followed by 
chemo-radiation therapy.  Targeted therapies such as epidermal growth factor receptor 
(EGFR)-specific antibody cetuximab are being used in combination with radiotherapy 
with some success (Leemans et al., 2011).   
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Despite vast improvements in surgical resection and radiotherapeutic techniques, 
survival rates of HNSCC patients have not significantly improved over the last thirty 
years (Leemans et al., 2011).  Several factors including molecular heterogeneity and field 
cancerization are responsible for residual disease and frequent secondary primary tumors, 
all which contribute to the lack of improvement in survival rates (Rothenberg, et al., 
2012).  Field cancerization, which increases the high risk of recurrence in these patients, 
was first described in 1953 (Slaughter et al., 1953) yet only recently evaluated and 
understood in a molecular context (Tabor et al., 2001; Leemans et al., 2011). The 
neighboring mucosal epithelium often appears normal at the macroscopic level; however, 
the epithelial cells themselves can be dysplastic as a result of a variety of incurred genetic 
alterations (Tabor et al., 2001).  The resulting pre-neoplastic regions of epithelium left 
behind in the surgical margins are responsible for the frequent development of 
metastases, second primary tumors, and add to the overall progression of HNSCC 
(Rothenburg et al., 2002; Leemams et al., 2011). Although much is known about the 
different causations of oral and oropharyngeal carcinomas (Agrawal et al., 2011; Park et 
al., 2011; Parfenov et al., 2014), the molecular mechanisms behind tumor cell invasion 
and metastasis have yet to be fully elucidated.  
 
Epithelial to mesenchymal transition (EMT)  
 The steps for HNSCC to progress from an in situ carcinoma to a locally invading 
cancer have been classically described by Hanahan and Weinberg (Hanahan and 
Weinberg, 2000) and include the pivotal cellular change referred to as the epithelial to 
mesenchymal transition (EMT). This transition is the result of a variety of key 
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morphologic and biochemical changes in an epithelial cell in which the cell loses cell-to-
cell adhesions and gains characteristics of a mesenchymal cell type.   In a normal context, 
EMT is critically important for gastrulation in development, wound healing, and fibrosis 
(Natarajan et al., 2014).  In the context of HNSCC, EMT is inappropriately activated and 
allows tumor cells to invade local tissue, regional lymph nodes, and metastasize to distant 
organs.   
EMT begins with the loss of epithelial marker E-CADHERIN, an epithelial 
glycoprotein critical for maintaining adherens junctions and cell-cell adhesion (Natarajan 
et al., 2014).  The downregulation of E-CADHERIN is considered the hallmark of EMT 
and is critical for this process to occur.  Other genes are upregulated during EMT include 
the mesenchymal markers N-CADHERIN and VIMENTIN, matrix metalloproteinases 
(MMP-3 and MMP-9), and mesenchymal integrins, all which increase cell motility and 
invasiveness through changes directly to the morphology of the cell and the cell’s 
interaction with the extracellular matrix (ECM) (Natarjan et al., 2014).  These markers 
have been found to be important predictors of metastasis and poor prognosis in HNSCC, 
highlighting the importance of EMT in the progression of the disease. Several different 
signaling cascades (TGF-B, Wnt, NOTCH) and downstream transcriptional regulators 
also influence the induction of the EMT program (Natarajan et al., 2014).  For example, 
basic helix-loop-helix (bHLH) transcription factors, TWIST and SNAIL-2, are associated 
with the initiation of EMT programs both in normal development and in cancer 
(Natarajan et al., 2014).  Other homeobox transcription factors, SIX1 and FOXC2, have 
also been implicated to indirectly repress E-CADHERIN (Yang et al., 2008).  The 
importance of EMT as a critical step in global metastatic cascade has been well 
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established, but the molecular understanding remains incomplete.  Further insight into 
these molecular mechanisms that regulate EMT in HNSCC are necessary to develop 
novel targeted therapies and increase survival rates in patients with this highly invasive 
and recurrent disease.   
 
LIM-only protein 4 (LMO4) 
LIM-only protein 4 (LMO4) is a nuclear adapter protein critical for the assembly of 
multiprotein transcriptional complexes that regulate epithelial proliferation and 
differentiation in development (Yamada et al, 2000; Visvader et al., 2001; Mizunuma et 
al., 2003; Sum et al., 2005; and Yamada et al., 2008). During embryogenesis, LMO4 has 
been reported to modulate gene expression in neural crest cells as a cofactor in SNAIL2-
mediated epithelial-mesenchymal transition (EMT) (Ferronha et al., 2013). This may 
account for the embryonic lethality and explain the phenotype of LMO4-null mice, 
manifested in failure of neural tube closure and exencephaly (Lee et al., 2005).  
LMO4 expression, in particular overexpression, also characterizes a variety of 
epithelial malignancies, including oral cavity carcinomas (Mizunuma et al., 20003) and 
in carcinoma of the breast (Sum et al., 2005; Visvader et al., 2001; Montañez-Wiscovich 
et al., 2009; Tian et al., 2010), in which it has been associated with reduced tumor cell 
differentiation and increased lymph node metastasis (Mizunuma et al., 2003, Kwong et 
al., 2011).  Additionally, LMO4 overexpression has also been reported in alveolar 
rhabdomyosarcomas (Armeanu-Ebinger, 2011).  In contrast, knockdown of LMO4 
reduced proliferation in human breast cancer cells and increased differentiation of mouse 
mammary epithelial cells (Sum et al., 2005).  
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The three remaining LMO proteins, LMO1, LMO2, and LMO3, have also been 
shown to have oncogenic properties when inappropriately expressed. LMO1 and LMO2 
are dysregulated in T-cell acute lymphoblastic leukemia (reviewed in Aifantis et al., 
2008; Rabbitts et al, 1998), while another study suggested that overexpression of LMO2 
was associated with progression of prostate cancer (Ma et al., 2006).  Likewise, LMO3 is 
upregulated in neuroblastoma (Ohira et al., 2005).  Furthermore, enforced overexpression 
of LMO1, LMO2, and LMO4 in transgenic mice was either sufficient to induce tumor 
development (Ohira et al., 2005, Sum et al., 2005) or induced a pre-malignant phenotype.  
The following body of work suggests that LMO4 may also play an important regulatory 
role in the progression of head and neck carcinoma. 
 
LIM domain-binding protein 1 (LDB1) 
LDB1, like LMO4, is a transcriptional adapter protein critical for bridging and 
stabilizing multiprotein transcriptional complexes. Also known as Chip in Drosophila 
melanogaster, LDB1 was first reported to mediate DNA-looping and bridge enhancer and 
promoter regions (Morcillo et al., 1997), which pointed to the importance of this adaptor 
protein for transcriptional regulation.  The protein’s LIM domain (LID) enables it to bind 
to the diverse group of LIM domain proteins including LIM-only and LIM-homeodomain 
proteins (Figure 2, top). Together with these proteins, LDB1 regulates cell-fate 
determination and diverse developmental processes in both embryonic and adult tissues 
(Matthews and Visvader, 2003).  Importantly, LDB1-null mice had severe anterior-
posterior patterning defects (Mukhopadhyay et al., 2003), which further highlights the 
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importance of this co-factor for the normal function of many transcriptional regulatory 
programs.  
Importantly, LDB1 expression in oral cavity carcinomas was found to correlate 
closely in abundance and location with LMO4 (Mizunuma et al., 2003).  LMO4 and 
LDB1 have also been reported to be frequently overexpressed in breast cancer, 
particularly in high-risk disease, and enforced expression of either gene inhibited 
mammary cell differentiation and promoted tumor cell invasion (Visvader et al., 2001). 
These studies support the notion that together, LMO4 and LDB1 may be important in the 
progression of head and neck carcinoma.  
 
Single-stranded binding proteins (SSBPs) 
Studies of LMO2 protein turnover in erythroid cells in the Brandt Lab resulted in 
the identification of a novel function for a family of LDB1-interacting proteins — 
protection of LMO proteins and LDB1 from ubiquitylation and subsequent proteosomal 
degradation (Xu et al., 2007). These putative single-stranded proteins, including single-
stranded binding protein-2 (SSBP2) and single-stranded binding protein-3 (SSBP3), were 
shown to inhibit LDB1 ubiquitylation by an E3 ubiquitin ligase, RING finger LIM 
domain-binding protein (RLIM, also known as RNF12) (Xu et al., 2007), and, in an 
LDB1-dependent manner, turnover of the LMO2 and LMO4 proteins. These results 
support the model that high SSBP expression levels within a cell can stabilize both 
LMO4 and LDB1, and SSBPs themselves can participate in the resulting multiprotein 
complexes that can then be recruited to target genes and influence transcriptional 
regulation (Figure 2, left).  On the contrary, when SSBP expression levels are low, LMO4 
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and LDB1 are degraded and stabilization of the multiprotein transcriptional complexes 
and recruitment to target genes is reduced (Figure 1.2, right).  In the context of a HNSCC 
cell, the expression levels of LMO4, LDB1, and SSBPs may alter direct gene targets 
involved in initiating or promoting EMT.  
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Figure 1.2 SSBPs	   protect	   LDB1	   and	   LMO	   proteins	   from	   RLIM-­‐mediated	  
ubiquitylation	  and	  stabilize	  multiprotein	  transcriptional	  complexes.	  	  A	  schematic	  of	   the	   primary	   structure	   of	   LDB1	   is	   shown	   at	   the	   top	   of	   figure,	   with	   three	   protein	  interaction	   domains	   demarcated,	   the	   dimerization	   domain	   (DD),	   LDB1/ChIP	  conserved	   domain	   (LCCD),	   and	   LIM-­‐binding	   domain	   (LID).	   High	   SSBP	   expression	  prevents	   the	   E3	   ubiquitin-­‐ligase	   RLIM	   from	   binding	   LDB1	   and	   promotes	   LDB1	  homodimerization	  with	   stabilization	  of	   the	   trimolecular	  protein	   complex.	   	   Low	  SSBP	  levels	  facilitate	  ubiquitylation	  of	  LDB1	  and	  LMO4,	  resulting	  in	  accelerated	  proteosomal	  degradation.	  	  The	  specific	  residues	  at	  which	  ubiquitin	  chains	  attach	  are	  unknown.	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Conclusion 	  
The following body of work reports several important findings regarding the role of 
LMO4, LDB1, and SSBPs in head and neck carcinoma.  First, LMO4, LDB1, and SSBP2 
and SSBP3 protein abundance were reciprocally correlated in a panel of human head and 
neck carcinoma cell lines.  Second, these proteins colocalized to sites of tissue invasion 
and/or metastases in human carcinoma samples.  Third, LDB1 gene inactivation 
profoundly inhibited tumor cell proliferation and invasiveness in vitro and in vivo and 
significantly decreased tumor vascularization.  Fourth, LDB1 gene inactivation alters 
RNA expression pathways involved in promoting invasiveness.  Lastly, global binding 
patterns of the LDB1 and SSBP2 were evaluated and common DNA motifs for global 
and specific target genes were determined. Together, these findings (Chapters III-VI) and 
the discussion that follows (Chapter VII) support the following two-part hypothesis: 1) 
the concordance between LMO4 and LDB1 protein abundance in HNSCC is likely the 
result of stabilization of these proteins by SSBPs; 2) the resulting multiprotein complex 
containing LMO4, LDB1, and SSBPs can alter specific transcriptional programs 
controlling invasiveness, lymph node metastasis, angiogenesis, proliferation/apoptosis, 
and likely cancer stem cells (CSCs) within HNSCC (Figure 1.3).   
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Figure 1.3 Possible mechanisms of progression in a head and neck 
squamous cell carcinoma cell as a result of overexpression of LMO4, LDB1, 
and SSBPs. A	  schematic	  of	  the	  different	  mechanisms	  of	  cancer	  progression	  which	   may	   be	   influenced	   or	   directly	   regulated	   by	   a	   complex	   containing	  LMO4,	  LDB1,	   and	  SSBPs	   in	  a	  head	  and	  neck	  squamous	  cell	  carcinoma	  cell.	  	  Increased	   invasion,	   increased	  proliferation,	  decreased	  apoptosis,	   increased	  lymph	   node	   metastasis,	   increased	   angiogenesis,	   and	   potentially	  maintenance	  of	  cancer	  stem	  cells	  are	  all	  potentially	  influenced	  at	  the	  level	  of	  transcriptional	   regulation	   by	   a	   prooncogenic	   complex	   containing	   LMO4,	  LDB1,	  and	  SSBPs	  and	  are	  explored	  or	  discussed	  in	  this	  dissertation.	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CHAPTER II 
 
MATERIALS AND METHODS 
 
Cell culture and reagents 
Human oral cavity carcinoma cell lines SCC-4 (catalog number CRL-1624), 
SCC-25 (catalog number CRL-1628), SCC-9 (catalog number CRL-1629), SCC-15 
(catalog number CRL-1623), and Cal-27 (catalog number CRL-2095) were obtained 
from ATCC, SCC-61 and UM-SCC-47 were contributed by Dr. Wendell Yarbrough 
(Vanderbilt University), HN-SCC-131 was provided by Dr. Susanne Gollin (University 
of Pittsburgh), and VU-SCC-1352 and VU-SCC-1729 came from the Barry Baker 
Laboratory for Head and Neck Oncology at Vanderbilt University, where they were 
derived. All oral cavity carcinoma cell lines were grown in Dulbecco’s modified Eagle 
medium (DMEM; Life Technologies-Thermo Fisher Scientific, Grand Island, NY) 
supplemented with 10% fetal bovine serum (FBS, Atlas Biologicals, Fort Collins, CO) 
and 1% penicillin/streptomycin and incubated in 50% CO2 at 37°C.  All oral cavity 
carcinoma cell lines were grown on T-175 cm2 flasks (CLS431080, Sigma-Aldrich, St. 
Louis, MO) to 60-85% confluency.  Fetal esophageal fibroblasts were grown in DMEM 
supplemented with 10% FBS and 1% penicillin/streptomycin and cultured in 50% CO2 at 
37°C. 
 
 
 
	  17	  
Antibodies 
To detect LDB1, LMO4, SSBP2, and SSBP3 in immunoblot and 
immunohistochemistry, the following antibodies were obtained: a polyclonal goat 
antibody for LDB1 (SC 11198) ordered from Santa Cruz Biotechnologies (Dallas, TX); a 
monoclonal rat antibody for LMO4 generously provided by Dr. Jane Visvader (Walter 
and Eliza Hall Institute, Melbourne, Australia) and described here (Sum et al, 2002); a 
custom polyclonal rabbit antibody for SSBP2 was generated by SDIX (Newark, DE) 
using a synthetic polypeptide antigen sequence to amino acids 163-243; and a polyclonal 
rabbit antibody for SSBP3 was generously provided by Dr. Lalitha Nagarajan and is 
described here (Liang et al., 2005). Control antibodies β-actin (ab44990) and 
glyceraldehyde phosphate dehydrogenase (GAPDH) (ab9485) were purchased from 
Abcam (Cambridge, MA).  
 
Immunoblot 
Immunoblots were carried out as previously described (Xu et al., 1995). Blots 
were imaged using Image J (Image J Software) and levels of LDB1, LMO4, SSBP2, 
SSBP3 were normalized to B-ACTIN and then normalized to the highest expresser.  
LDB1 knockout clones and their effects on LMO4 were evaluated using a GADPH 
loading control. 
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Human Tissue Preparation 
Individual tumor samples 
Oral cavity carcinomas, oropharyngeal carcinomas, and regional lymph nodes 
were collected from consented patients (IRB # 030062) during operative procedures at 
Vanderbilt University hospitals.  Within thirty minutes of removal from each patient, the 
tissue was placed in a biopsy cassette and submerged in 10% formalin for no longer than 
24 to 48 hours.  The cassettes containing the tissue were then moved to 70% ethanol for 
transportation to Translational Pathology Shared Resource (TPSR) for paraffin 
embedding and subsequent sectioning.  
 
TMA preparation 
 Tumor and adjacent normal tissues were collected from consented patients (IRB # 
030062) during operative procedures.  Within thirty minutes of removal from each 
patient, the tissue was placed in a biopsy cassette and submerged in 10% Formalin for no 
longer than 24 to 48 hours.  The cassettes containing the tissue were then moved to 70% 
ethanol for transportation to TPSR for paraffin embedding. Slides and blocks were 
reviewed by Dr. Kim Ely in the department of surgical pathology (Vanderbilt University) 
to determine if the specimen was suitable for use. TMAs were generated from blocks pre-
selected by Brandee Brown (manager of the Head and Neck Cancer Tissue Biorepository 
and Barry Baker Head and Laboratory, Vanderbilt University). Samples were separated 
by 1.5mm from one another and were punched in triplicates for statistical purposes. 
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Immunohistochemistry: LMO4, LDB1, SSBP2, SSBP3 
Immunohistochemistry performed by the TPSR at Vanderbilt University, 
Nashville, TN as described. Slides were placed on the Leica Bond Max IHC stainer. All 
steps besides dehydration, clearing and cover-slipping were performed on the Bond Max. 
Slides were de-paraffinized. Heat induced antigen retrieval was performed on the Bond 
Max using their Epitope Retrieval 1 solution for 10 minutes. Slides were incubated with 
antibody (anti-LDB1 1:500 dilution; anti-LMO4 1:700 dilution; anti-SSBP2 1:1200 
dilution; anti-SSBP3 1:500 dilution) for one hour and followed by the appropriate 
biotinylated secondary antibody for 30 minutes at 1:200 dilutions.  The Bond Polymer 
Refine detection system was used for visualization. Slides were then dehydrated, cleared 
and cover-slipped. 
 
CRISPR/Cas9-mediated deletion of LDB1 
CRISPR/Cas9 system was used to target LDB1 (Figure 2.1) as previously 
described (Wang et al., 2014) using the following guide RNAs 5’-3’ sequences 
(Integrated DNA Technologies, Coralville Iowa) as follows:  
 
LDB1 gRNA1 top (CACCGACCATGCTGGATAGGGATGT),  
LDB1 gRNA1 bottom (AAACACATCCCTATCCAGCATGGT),  
LDB1 gRNA2 top (CACCGGTAGGCGGATACATGGGAGT),  
LDB1 gRNA2 bottom (AAACACTCCCATGTATCCGCCTAC).  
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 VU-SCC-1729 cells were transduced with retrovirus expressing the guide RNAs 
targeting LDB1 exon 1 (gRNA1), exon 2 (gRNA2), and an empty vector.   
 
Viral production and transduction 
100 pmoles of top and bottom strand oligonucleotides were mixed and 
phosphorylated overnight with 2 units of T4 Polynucleotide Kinase (NEB) in T4 ligase 
buffer.  Phosphorylation reactions were then adjusted to 200 mM NaCl and placed in a 
95°C heat block for five minutes.  After five minutes, the heat block setting was adjusted 
to 23°C, and reactions were left in the heat block until the lower temperature was 
reached.  33 fmoles of each duplex were then ligated to 10 fmoles of plentiCRISPR 
(Shalem et al., 2014) that had been digested with BsmBI (NEB), dephosphorylated with 
alkaline phosphatase, and gel purified.  Ligation reactions were transformed into 
Figure 2.1 Guide RNAs target LDB1 exons to generate CRISPR/Cas9 
knockout.  (Top) Full length LDB1 mRNA is depicted with 11 exons (grey 
boxes). (Middle) Exons 1 and 2 enlarged to show target of exon 1 by guide 
RNA 1 (gRNA1).  (Bottom) Exons 1 and 2 enlarged to show target of exon 2 
by guide RNA 2 (gRNA2).  	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chemically competent XL1 blue E. coli.  A single colony of each construct was picked 
and expanded; a portion was used to prepare DNA for analytical restriction digest and 
sequencing with U6 promoter primer (ACTATCATATGCTTACCGTAAC) to verify 
inserts.  Maxiprep DNA was prepared from 500 mL saturated culture using a modified 
alkaline lysis/LiCl and PEG 8000 precipitation protocol.  
1 pmole of each recombinant plentiCRISPR was mixed with 2 pmoles of both 
pSPAX2 (GAG/POL, Addgene) and pVSVG (ENV, Addgene) and transfected in 
triplicate to log phase HEK 293t cells using HEPES buffered saline/Calcium Phosphate.  
Prior to transfection each replicate of cells was grown in a 10 centimeter dish to 50-70% 
confluence (5-7 x 106 cells per dish) in 10 mL IMDM media at 37°C and 5% CO2.  12-18 
hours after transfection, media was aspirated and exchanged with 6 mL fresh IMDM.  
Conditioned media containing virus was removed 24 hours later and again replaced with 
fresh IMDM, and collected once more after an additional 24 hours.  Individual viral 
supernatants from replicates of both time points were pooled and centrifuged briefly at 
800 x g to remove cellular debris, then subjected to ultracentrifugation in a Beckman 
Ti60 rotor for 3.5 hours at 100,000 x g.  The viral pellet was resuspended in 1/10 the 
starting volume of IMDM and stored at -80°C. 
 
VU-1729-LDB1 generation 
Viruses were serially titered on VU-SCC-1729 cells. Growth and viability were 
estimated by vital dye staining and cell counting, with comparison to mock-transduced 
cells. Cells were selected with Puromycin (7 µg/mL), which was added to the medium 
36 hours after transfection.  Transduced cells were then cultured for 48 hours in selective 
	  22	  
medium. Single colonies were transferred to a 96-well plate and grown in selective 
medium. Monoclonal lines were screened for LDB1 and LMO4 via immunoblot.  Final 
monoclonal cell lines were used in matrigel invasion, co-culture, xenograft, and RNA-seq 
assays. 
 
In vitro proliferation assay 
 VU-SCC-1729 and VU-1729-2:7 cells were incubated in 6-well plates containing 
DMEM (Gibco, #11330-032) supplemented with 10% fetal bovine serum (FBS, Atlas 
Biologicals, #F-0500-D), 1% Penicillin/streptomycin, incubated at 50% CO2, 37°C.  
Initially (Day 0), a total of 46,000 cells/well were plated into four separate wells.  The 
contents of one well was harvested daily for viable cell count by trypan blue exclusion. 
Assay was performed in biological triplicate.  Standard statistical analysis is reported as 
mean +/- SEM and unpaired student t-tests were used to determine statistical significance 
of differences in mean cell number.  P < 0.05 was considered statistically significant 
(GraphPad Software, La Jolla, CA) 
 
 
Matrigel invasion assay 
Invasion was measured using a modified Boyden Chamber Matrigel method 
(Albini et al., 1987). Transwell 8.0 µm permeable membrane chambers (Costar Corning, 
Corning, NY) were prepared as follows: the superior surface of membranes were coated 
with 1:5 mixture of Matrigel (BD Biosciences, Franklin Lakes, NJ, 354230) in Opti-
MEM (Gibco, 31985-070) and the inferior surface of membranes were coated with 1:20 
mixture of Matrigel in Opti-MEM. After letting the Matrigel solidify at 37°C for 1 hour, 
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Matrigel was blocked with 1% bovine serum albumin for 30 minutes at 37°C.  VU-SCC-
1729 and cell line derivatives were serum starved for 24 hours in Opti-MEM reduced 
serum media prior to being trypsonized, counted, and plated at a density of 100,000 
cells/chamber (Figure 2.2). 
 
 
Chambers were submerged in DMEM (Gibco, 11330-032) supplemented with 10% FBS, 
1% Penicillin/Streptomycin and allowed to invade at 37°C.  After 6 hours, cells were 
fixed with 10% formalin and stained with crystal violet. Multiple sections from each 
transwell image were randomly selected and counted from at least two transwell 
chambers per biological replicate.  Data is from at least 2 biological replicates. Standard 
statistical analysis is reported as mean +/- SEM and unpaired student t-tests were used 
Figure 2.2 Matrigel invasion schematic.  Serum-starved HNSCC cells (blue circles) 
are plated on top of matrigel in serum-free conditions.  HNSCC cells begin to invade 
down into the matrigel in response to serum-containing media below. Cells are trapped 
in the porous membrane and fixed for subsequent quantification.   	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determine statistical significance of differences in mean cell number.  P < 0.05 was 
considered statistically significant (GraphPad Software, La Jolla, CA) 
 
Organotypic Reconstruct Assay 
VU-SCC-1729-P (parental) and VU-1729-2:7 (LDB1 knockout) lines were grown 
in 17 day organotypic cultures (OTC) as previously described (Andl et al., 2010) with 
specific or changed details below (Figure 2.3).  
 
Day 1. 16 mL/6-well plate high concentration rat-tail collagen (Corning, 354249) 
was prepared on ice per BD instructions.  A final concentration of 2.2 mg/mL collagen 
was obtained by diluting high concentration collagen with 1 N NaOH and sterile water.  
Figure 2.3 Organotypic co-culture schematic. HNSCC cells (blue circles) are plated 
on top of a mixed matrix of collagen and fibroblasts (yellow ovals) in serum-free 
conditions.  HNSCC cells (blue circles) begin to invade down into the mixed matrix in 
response to serum-containing media and signals from fibroblasts (yellow ovals).  The 
result of this co-culture is a 3-dimentiontial tissue that can be fixed, sectioned, and 
stained to observe level of invasion. 	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Transwell inserts were added to a deep well plate.  The bottom layer consisted of the 
following layers, which were mixed in order on ice (table below): 
 
 
 1 well (µl) 3 wells (µl) 1 plate (µl) 
10xEMEM 98.3 295 590 
FBS (Hyclone) 100 300 600 
L-glutamine 8.3 25 50 
Sodium bicarbonate 20 60 120 
Collagen (2.2mg/mL) 800 2400 4800 
 
 
The bottom collagen layer was incubated at 37°C for at least 20 minutes to let the matrix 
solidify. During this time, fetal esophageal fibroblasts were counted and adjusted to the 
cell concentration to 300,000 cells/mL, and used in the top layer, which was made of up 
the following layers, mixed in order on ice (table below): 
 
 1 well (µl) 3 wells (µl) 1 plate (µl) 
10xEMEM 275 825 1650 
FBS (Hyclone) 308 925 1850 
L-glutamine 25 75 150 
Sodium bicarbonate 58 175 350 
Collagen (2.2mg/mL) 1750 5250 10.5mL 
Matrigel 583 1750 3500 
Fibroblasts 250 750 1500 
 
 
The top layer was incubated at 37°C for 1 hour to allow the matrix to harden.  After the 
top and bottom layers were hardened, 15mL of fetal esophageal fibroblast media was 
added to the bottom of the wells and 2 mL of media to the top.  
Day 7. The media was changed to DMEM+F-12 (DMEM from Sigma, F-12 from 
Gibco) mixed in a 3:1 ratio. 15 mL media was added to the bottom, 2 mL was added to 
the top and the culture was incubated for 1 hour at 37°C.  Human head and neck 
	  26	  
squamous cell carcinoma cells (VU-SCC-1729-P and VU-1729-LDB1 KO clones) were 
counted and adjusted to 1x107 cells/mL in media containing serum.  DMEM+F12 media 
was aspirated from the culture (both top and bottom chambers) and 50 µl of cells were 
added to each well, forming a triangle pattern of droplets (schematic below), and 
incubated at 37°C for 2 hours.   
 
 
 
After 2 hours, Epidermalization I media (table below) was added to the plate (15 
mL to the bottom, 2 mL to the top). 
 
 
 
 
 
 
Epidermalization 
I 
(17mL/well, 
102mL per plate) 
Epidermalization II 
(17mL/well, 102mL 
per plate) 
Epidermalization III 
(13mL/well, 156mL 
per plate) 
Epidermalization III 
serum-free 
(13mL/well, 78mL per 
plate) 
DMEM (+CaCl2) 36.25 36.25 23.7 23.7 
F-12 12 12 23.7 23.7 
L-glutamine 1 1 1 1 
Hydrocortisone 0.1 0.1 0.1 0.1 
ITES (500x) 0.1 0.1 0.1 0.1 
O-phosphory-ethanolamine 0.1 0.1 0.1 0.1 
Adenine 0.1 0.1 0.1 0.1 
Progesterone 0.1 0.1 - - 
Triiodothyronine 0.1 0.1 0.1 0.1 
Newborn calf serum 0.05 (chelated) 0.05 1 - 
Gentamycin 0.05 0.05 0.05 0.05 
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Day 9. Epidermalization II media (table above) was added to the plate (15mL to 
the bottom, 2mL to the top). 
Day 11. Epidermalization III media (table above) was added to the plate (15mL to 
the bottom, 2mL to the top). 
Day 13. Epidermalization III media (table above) was added to the plate (13mL to 
the bottom of the plate only). 
Day 15. Epidermalization III serum-free media (table above) was added to the 
plate (13mL to the bottom of the plate only).  
Day 17.  Cultures were harvested on Day 17 and fixed in 10% formalin overnight.  
Cultures were paraffin embedded, sectioned and stained with hematoxylin and eosin 
(H&E) by the TPSR Core (Vanderbilt University). Cell line OTCs were performed in 
duplicate. Area of invasion was measured from multiple views of OTC sections and 
calculated using Image J (Image J software).  Standard statistical analysis is reported as 
mean +/- SEM and unpaired student t-tests were used to determine statistical significance 
of differences in mean invasion area.  P < 0.05 was considered statistically significant 
(GraphPad Software, La Jolla, CA) 
 
Xenografts 
 Athymic nude male animals were obtained from The Jackson Laboratory and 
housed under pathogen-free conditions.  All experiments were performed in accordance 
with AAALAC guidelines and with Vanderbilt University Institutional Animal Care and 
Use Committee approval.  For tumor progression studies in vivo, 4-5 week old nude male 
mice were injected subcutaneously into the dorsal flank with (500,000 cells + matrigel at 
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a final volume of 100 µL per mouse) as described previously (Brantley-Sieders, 2011).  
Implantation of tumor cells was carried out under isoflurane anesthesia and every effort 
was made to minimize suffering.  VU-SCC-1729-P (parental) cells and VU-SCC-1729-
2:7  (CRISPR/cas9-mediated deletion of LDB1 subline) cells were injected into the left 
and right contralateral flanks, respectively (Figure 2.4).  
 
Resulting tumors were measured over time using caliper measurements of tumor length 
and width.  Measurements were taken for the following time points: Day 0, Day 5, Day 
10, Day 13, Day 20, and Day 23.  Tumor volume was quantified using the following 
formula (Bergers, 2000):  
 
(Eq. 2.1)  Tumor Volume = (Length x Width)2 x (0.52) 
Figure 2.4 Schematic of xenograft injections. Dorsal flanks of athymic nude mice 
were injected subcutaneously with VU-SCC-1729-P cells on the left flank and VU-
SCC-1729-2:7 cells on the right flank. Tumors were allowed to grow for 23 days. 	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Tumors were harvested on Day 23 post-injection and processed for histology. Ten 
independent mice were used (n = 10). Xenograft tumors were dissected from mice and 
fixed in 10% formalin for 48 hours.  
 
PCNA Immunohistochemistry 
Tissue processing, ET AL&E staining, and immunohistochemistry for Cleaved 
Caspase 3 was performed by the Vanderbilt Translational Pathology Shared Resource.  
PCNA immunohistochemistry analysis was performed as described previously (see 
Brantley-Sieders et al. 2011 Cancer Res 71: 976-87; Youngblood et al. 2015 Mol Cancer 
Res 13: 524-37). Photomicrographs acquired on an Olympus CK40 inverted microscope 
through an Optronics DEI-750C charge-coupled-device video camera using CellSens 
capture software. CellSens software was also used to quantify the average percentage of 
PCNA or Cleaved Caspase 3 positive nuclei relative to total in 3 to 4 fields/sample (10-
20X magnification) as described previously. Data are a representation of 5-7 independent 
tumors/condition. Standard statistical analysis is reported as mean +/- SEM and unpaired 
student t-tests were used to determine statistical significance of differences in cell 
proliferation.  P < 0.05 was considered statistically significant (GraphPad Software, La 
Jolla, CA) 
 
vWF Immunofluorescence 
Tissue processing, H&E staining was performed by the Vanderbilt Translational 
Pathology Shared Resource. vWF immunofluorescence analysis was performed as 
described previously (see Brantley-Sieders et al. 2011 Cancer Res 71: 976-87; 
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Youngblood et al. 2015 Mol Cancer Res 13: 524-37). Photomicrographs acquired on an 
Olympus CK40 inverted microscope through an Optronics DEI-750C charge-coupled-
device video camera using CellSens capture software. CellSens software was also used to 
quantify the microvascular density (vWF positive blood vessels) in 3 to 4 fields/sample 
(10-20X magnification) as described previously. Data are a representation of 5-7 
independent tumors/condition. Standard statistical analysis is reported as mean +/- SEM 
and unpaired student t-tests were used to determine statistical significance of differences 
in mean microvessel density.  P < 0.05 was considered statistically significant (GraphPad 
Software, La Jolla, CA) 
 
RNA-seq Analysis 
 Total RNA was isolated from parental control (VU-SCC-1729-P) and CRISPR-
cas9 LDB1 knockout (VU-1729-2:7) cells in biological triplicates (Qiagen RNeasy kit).  
RNA-seq libraries were generated and sequenced by the Vanderbilt Technologies for 
Advanced Genomics (VANTAGE) Core at Vanderbilt University, Nashville, TN.  
Bioinformatics was performed by Yan Guo (Vanderbilt University, Nashville, TN) and 
the significantly impacted pathways were analyzed using Advaita Bio’s iPathwayGuide 
(Advaita Bio, Plymouth, MI; http://et al.advaitabio.com/ipathwayguide).  RNA-seq data 
were submitted to Gene Expression Omnibus and assigned accession number GSE79183 
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE79183). 
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Chromatin Immunoprecipitation  
Standard chromatin immunoprecipitation (ChIP) followed formaldehyde fixation 
and sonication conditions described below in ChIP-exo. Protocol and reagents from EZ 
ChIP kit (Upstate Biotechnologies, 17-371) were used to lyse, wash, and elute 
immunoprecipitates, and DNA was purified using standard phenol/chloroform isolation. 
Real time-quantitative PCR (RT-qPCR) was performed using SYBR® Green Quantitative 
RT-qPCR Kit (BIO-RAD, 172-5140) was used to evaluate occupancy at target genes. 
Forward (F) and reverse (R) primers are listed for each target gene below.  
 
CDC27 
(F): CTGCAGCACCGTCATCCT 
(R): GTAACGGTCGCTGGTGAGTT 
CDC27-exon 
(F): TCCCAACAATGAAAGAGTAAAGC 
(R): TTGCAGAAGGGGAACAAATC 
MIR3687 
(F): GGATGCGTGCATTTATCAGA 
(R): GTTTCTCAGGCTCCCTCTCC 
CDH11-promoter 
(F): TTAGGATTCTACTCAAGAGAACAGGA 
(R): TTTATGTTGTTTCTTTTGTTTATCTGC 
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CDH11-exon 
(F): TCCTGGACCTTGACAATGAA 
(R): TGACTCTGGTGATGGGAACA 
CKAP2L-promoter 
(F): TGGGTATTCTATTGTGCGGATA 
(R): CAGCATTATTCATAATAGCCAAAAA 
HMGA2-intron 
(F):  AGCCAAGCCAGGCATCTAAG 
(R): TCTTGTGTTGAGTTTAATTTCAGAGG 
 
ChIP-exo  
 Chromatin immunoprecipitation followed by exonuclease digestion (ChIP-exo) 
was used to acquire genome-wide occupancy information for LDB1 and SSBP2 in VU-
SCC-1729 cells as was previously developed (Rhee et al., 2012) and described below.   
 
Formaldehyde fixation and sonication 
 Adherent VU-SCC-1729 cells were grown in 1.75 L flasks under normal 
conditions to 85% confluency. Growth medium was removed and washed away with 
phosphate buffered saline (PBS).  Cells were fixed in a 1% formaldehyde PBS solution 
for 10 minutes after which the reaction was quenched with excess glycine.  Cross-linked 
cells were washed again with cold PBS (4°C), scraped off flask and pelleted into flasks 
containing ~150 million cells each.  Cell pellets were stored at -80°C until ready for cell 
lysis and sonication. 
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 Frozen pellets of cross-linked cells were thawed on ice, re-suspended in cell lysis 
buffer (final concentration 10mM Tris pH 8.0, 10mM NaCl, 0.5% NP40, plus complete 
protease inhibitors) and lysed on ice for 10 minutes. Cells were centrifuged (4°C) at 2500 
rpm for 5 minutes and re-suspended in nuclear lysis buffer (final concentration 50mM 
Tris pH 8.0, 10mM EDTA, 1.0% SDS, plus complete protease inhibitors) and lysed on 
ice for 10 minutes. Cells were diluted with cold immunoprecipitation dilution buffer 
(final concentration 20 mM Tris ph 8.0, 2mM EDTA, 150mM NaCl, 1% Triton x-100) 
and transferred to 1.5 mL tubes containing 300 µL cell lysate each (~6.6 million cells/100 
µL).  Tubes were transferred to a chilled (4°C) biorupter (Diagenode Biorupter, 
B01020001) water bath and were sonicated on high for a total time of 40 minutes (4 x 10 
minute sessions of 30 seconds ON/30 seconds OFF). Samples were put on ice between 
each session until water bath returned to 4°C.  After sonication, samples were centrifuged 
at 14,000 rpm for 10 minutes at 4°C.  Supernatants were transferred to new tubes and 
used for immunoprecipitation. 
 
Chromatin immunoprecipitation 
 Antibodies (SSBP2 and LDB1) and sonicated extract were incubated overnight at 
4°C. Magnetic Protein G beads (New England BioLabs, S1430S) were added to 
antibody/extract mixture and incubated for 1 hour at 4°C.  Tubes were placed against a 
magnetic rack, supernatant was removed, and beads were washed for three minute-
rotations in the following buffers: RIPA Salt buffer (final concentration 1X PBS, 1% 
NP40, 0.5% NaDeoxycholate, 0.1% SDS); LiCl Buffer (final concentration 100 mM Tris 
pH 8.0, 500 mM LiCl, 1.0% NP40, 1.0% NaDeoxycholate); FAT buffer (final 
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concentration 40 mM Tris pH 8.0, 7 mM EDTA, 56 mM NaCl, 0.2% SDS, 0.375% 
TritonX-100); Tris-HCl butter (final concentration, 10 mM Tris pH 7.5).  After last wash 
(Tris-HCl buffer) is removed, on-bead library preparation began (see below).  
 
Library preparation for Illumina 
 Polishing master mix (ddH20, 10x NEB2 buffer, 1 mg/mL BSA, 3 mM dNTPs, 3 
U/µl T4 DNA polymerase) was added to the beads, pipeted to mix, and incubated in a 
thermomixer at 12°C for 20 minutes at 1400 rpm. Tubes were placed against a magnet, 
polishing mix removed, and washed with 10mM Tris buffer.  
 Kinase master mix (ddH20, 10x T4 DNA ligase buffer, 10 U/µl T4 polynucleotide 
kinase) was added to the beads, pipeted to mix, and incubated in a thermomixer at 37°C 
for 30 minutes at 1400 rpm.  Tubes were placed against a magnet and kinase mix was 
removed.  
 A-tailing master mix (ddH20, 10x NEB2 buffer, 3 mM dATP, 5 U/µl Klenow 3’-
5’ exo minus) was added to the beads, pipeted to mix, incubated in a thermomixer at 
37°C for 30 minutes at 1400 rpm.  Tubes were placed against a magnet and A-tailing mix 
was removed.  
 Master ligation mix (ddH20, 1mg/mL BSA, NEB 10x T4 DNA ligase buffer, NEB 
400 U/µl T4 DNA ligase) was aliquoted to fresh tubes (one tube per sample) and 
immediately mixed with an Index Adapter (different for each sample). Ligation mixes 
(containing unique Index Adapters for each sample) were added to the beads, pipeted to 
mix, incubated in a thermomixer at 25°C for 2 hours at 1400 rpm. Tubes were placed 
against a magnet and ligation mix was removed. Samples were then washed three 
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different times for 3 minutes each with aspiration of supernatant in between using FAT 
buffer, LiCL Buffer, and 10 mM Tris-HCL buffer.  
 Following the last wash, Phi-29 master mix (ddH20, 1mg/mL BSA, 10x Phi29 
reaction buffer, 3mM dNTPs, 10 U/µl Phi29 DNA polymerase) was added to the beads, 
pipeted to mix, and incubated in a thermomixer at 30°C for 20 minutes at 1400 rpm.  
Tubes were placed against a magnet and Phi-29 mix was removed. 
 Kinase master mix (ddH20, 1mg/mL BSA, 10x T4 DNA ligase buffer, 10 U/µl T4 
PNK) was added to the beads, pipeted to mix, and incubated in a thermomixer at 37°C 
for 20 minutes at 1400 rpm.  Tubes were placed against a magnet and kinase mix was 
removed. 
 Lambda exonuclease master mix (ddH20, 1mg/mL BSA, 10x lambda exonuclease 
reaction buffer, 5 U/µl lambda exonuclease) was added to the beads, pipeted to mix, and 
incubated in a thermomixer at 37°C for 30 minutes at 1400 rpm.  Tubes were placed 
against a magnet and lambda exonuclease mix was removed. 
 RecJf exonuclease master mix (ddH20, 1mg/mL BSA, 10x NEB2 buffer, 30 U/µl 
RecJf exonuclease) was added to the beads, pipeted to mix, and incubated in a 
thermomixer at 37°C for 30 minutes at 1400 rpm.  Tubes were placed against a magnet 
and RecJf exonuclease mix was removed. Samples were washed overnight in FAT buffer 
at 4°C.  The following morning, samples were washed 5 times with each of the following 
buffers: RIPA buffer, RIPA salt buffer, LiCl Buffer.  After the last wash was removed, 
samples were eluted off the beads with ChIP elution buffer and then were incubated at 
65°C for 15 minutes on a heat block.  Tubes were placed against a magnet and the 
supernatant was transferred a new tube with the addition of 20 mg/mL proteinase K, then 
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incubated at 65°C for 30 minutes on a head block.  To reverse crosslinks, samples were 
placed on a heat block at 95°C for 10 minutes.  DNA was then extracted by standard 
phenol:chloroform method. Following ethanol precipitation dried DNA pellets were 
resuspended in 10 µl ddH20 and transferred to 0.5 mL PCR tubes.  
 Primer master mix (ddH20, 1mg/mL BSA, 10xPhi29 reaction buffer, 3 mM 
dNTPs, FX-15 primer) was added to resuspended DNA pellets and pipeted to mix. 
Samples were run in the thermocycler using the following program: 95°C for 5 minutes, 
40°C for 10 minutes, 30°C for five minutes, 30°C hold (add 1 µl of 10U/µl Phi29 DNA 
polymerase at this step), 30°C for 20 minutes, 65°C for 10 minutes, and 4°C hold.  
At the end of the thermocycler program, A-tailing master mix (ddH20, 10x NEB2 
buffer, 3mM dATP, 5 U/µl Klenow 3’ to 5’ exo minus) was added to the samples, 
pipeted to mix, and incubated in a thermocycler at 37°C for 30 minutes and then at 75°C 
for 20 minutes. 
At the end of the thermocycler program, ligation master mix (ddH20, 10x T4 
DNA ligase buffer, 15 uM ExA1-58/13 adapter, 600 U/µl T4 DNA ligase) was added to 
the samples, pipeted to mix, and incubated in the thermocycler at 25°C for 2 hours.  
Samples were either frozen at this step (-80°C) or directly moved to the following 
Ampure purification. 
Ligation samples were combined with 1.8 volumes of AMPure beads and pipeted 
for 20 seconds to mix. Samples were then placed on a magnetic rack and supernatant was 
discarded. Beads were washed with 70% ethanol 3 times and dried at room temperature 
for 10 minutes. DNA samples were then eluted from dry beads using 10 mM Tris buffer 
and transferred to PCR tubes. 
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Q5 LM-PCR master mix (ddH20, 5x Q5 reaction buffer, 10 mM dNTPs, 20 µM 
P1.3 primer, 20 uM P2.1 primer, 2 U/µl Q5 hot start DNA polymerase) was added to the 
DNA samples, pipeted to mix, and run in the thermocycler with the following program: 
98°C for 30 seconds for 1 cycle; 98°C for 10 seconds, 52°C for 30 seconds, 72°C for 20 
seconds for 20 cycles, 72°C for 2 minutes, 4°C hold.   
Resulting PCR products between 200-500 base pairs in length were purified by 
agarose gel and gel extraction kit (Qiagen, 28704). Purified DNA concentration was 
measured (Qubit fluorometer) and sent to the Vanderbilt VANTAGE sequencing core for 
high-throughput next generation sequencing.  Resulting sequence files were returned to 
our lab in .bam format and analyzed in the sequencing analysis pipeline below. 
 
Sequencing analysis pipeline 
 Sequencing files obtained from the Vanderbilt VANTAGE core were analyzed 
using Terminal command line.  The specific tools used in the following analysis pipeline 
were either publically available scripts or custom scripts courtesy of Byran Venters 
(Vanderbilt University, Nashville, TN).  
 Sequencing files (.bam) were sorted using a SAM Tools script called sort and the 
command: 
 
(Eq. 2.2)  Time /pathtoSamtools/samtools sort 
/pathtosavedoutputPrefix/ input_sorted 
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The script output was a sorted .bam file, which was then indexed with a SAM Tools 
script called index using the following command: 
 
(Eq. 2.3)  Time /pathtoSamtools/samtools index 
/pathtosavedoutputPrefix/ input_sorted.bam 
 
 
The script output was an indexed .bai file. The following step isolated only uniquely 
mapped reads from the sorted.bam file by using a SAM Tools script called with the 
following command: 
 
(Eq. 2.4)  time /pathtosamtools/samtools view –F 4 –q 1 –hb 
/pathto/input_sorted.bam > ./output.sorted_uniq.bam 
 
 
The output containing uniquely mapped reads was then converted to a .bed file using a 
BED Tools script called bamtobed and the command: 
 
(Eq. 2.5)  time /pathtobedtools /bedtools bamtobed –i 
/pathto/input_sorted.bam > .pathto/output_sorted.bed 
 
 
 
The output .bed file was then sorted using BED Tools and the command: 
 
 
 
(Eq. 2.6)  time /pathtobedtools /bedtools sortedbed –i 
./output_uniq.bed > output_uniq_sort.bed 
 
 
	  39	  
The .bed file containing uniquely mapped reads was indexed using a python script called 
tabs2genetrack and the command: 
 
(Eq. 2.7)  time python /pathytotabs2genetrack 
/tabs2genetrack.py –i ./output_uniq.bed –f bed –o 
output_uniq.idx 
 
 
 
The output index file was used to call peaks using a custom python script called 
multiprocess_gff3 and the command: 
 
 
(Eq. 2.8)  time python /pathto/genetrack/multiprocess_gff3.py –
s 20 –e 40 ./output_uniq.idx 
 
 
The output was a .gff file containing information regarding the standard deviation 
around the called peaks. A non-zero number for standard deviation indicated that there 
were multiple reads around a specific unique region.  Standard deviations of zero were 
considered ‘orphan’ peaks, and were not able to be paired with another peak.  The .gff 
file containing both orphans and non-orphans was peak paired using a custom python 
script called cwpair_gff3_rzr142 and the command: 
 
(Eq. 2.9) time python /pathto/cwpair_gff3_rzr142.py –u 0 –d 80 
–b 3 /pathto/input_peakscalled.gff 
 
 
 
The output was a simplified cwpair.gff file containing the paired peaks and the 
coordinates of the midpoint peak value.  The locations of these paired peaks were then 
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mapped to a meaningful reference segment. For this analysis, they were mapped to the 
distance of the nearest human genome (HG19) transcriptional start site (TSS) using a 
python script called map_segment_to_segment and the command: 
 
(Eq. 2.10) time python /pathto/map_segment_to_segment.py –f 
/pathto/referenceTSS_hg19.csv –t 
/pathto/input_S_cwpair.gff –S 3 –E 4 –u 2000 –d 2000 
 
 
The output file is .gff file that contained the information of the paired peaks that were 
within the defined upstream and downstream limits of a transcriptional start site within 
the human genome.  The sequence information at those regions was obtained using a 
python script called fastaextract and the command: 
 
(Eq. 2.11) time python /pathTo/fastaextract.py –g 
/pathTo/compiled_mm10orHg19_build.fa –u 40 –d 40 
/pathTo/input_peakPairMidpoint.gff 
 
 
The output was a fasta.fa file that contained the actual sequences for all of the paired 
peaks.  This file was evaluated further in the motif qualification pipeline below. 
 
Motif qualification pipeline 
 
The fasta.fa files contained DNA sequence information for the regions of 
occupancy of LDB1 and SSBP2. Due to the nature of the algorithms used to “peak call” 
peaks in the ChIP-exo sequencing analysis pipeline, ChIP-exo positive results were 
returning two types of peaks: clustered peaks and distinct peaks.  The clustered peaks 
were unable to be validated on target genes for either LDB1 or SSBP2.  The distinct 
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peaks were validated using RT-qPCR on target genes. Therefore, the motif qualification 
was used to further analyze only distinct peaks. 
 The “called peaks” were sorted first by rank order. This organized the “called 
peaks” with the most sequence tags (strongest/highest peaks compared to background) 
first and the “called peaks” with the fewest sequence tags (lowest peaks compared to 
background) last.  The top peaks were checked graphically based on the following 
characteristics:   
i. Must have multiple sequence tags on both the forward and reverse 
strand (excluded orphans and likely PCR artifacts all mapping to 
the same nucleotide); 
ii. The distribution of the sequence tags must span several different 
nucleotides; 
iii. The peak must appear to be distinct, not a series of clustered peaks 
iv. The peak must appear in a promoter or intronic region compared to 
a proximal gene. 
This checklist was followed until ~35 of the top “distinct peaks” that were in 
promoter regions and the ~35 top “distinct peaks” that were in intronic regions.  Three 
files were generated containing the DNA sequences associated with the distinct peaks (1: 
Promoter peak sequences; 2: Intronic Peak sequences; 3: Promoter + Intronic peak 
sequences). Biostatistician Yan Guo analyzed each of the three files described above and 
found three statistically significant and repeatedly represented motifs within each group 
of DNA sequences.  
	  42	  
The 3 motifs discovered from each of the 3 DNA sequence files were compared to 
a variety of known motif databases using the Benso Lab STAMP analysis (alignment, 
similarity, and database matching for DNA motifs; University of Pittsburgh, Pittsburgh, 
PA; http://et al.benoslab.pitt.edu/stamp). The outputs from these analyses were lists of 
likely binding motifs that may be present within particular peak regions and the 
corresponding transcription factors that are predicted to bind there.  
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CHAPTER III 
 
EXPRESSION ANALYSIS OF LMO4, LDB1, SSBPS 
 
Introduction 
 Investigation of the relevance of SSBPs, LDB1, and LMO4 in head and neck 
carcinoma began with replication of the important findings of Mizunuma et al., 2003.  
They reported that LMO4 and LDB1 were frequently and, importantly, concordantly 
upregulated in oral cavity squamous cell carcinomas and both proteins were shown to 
localize to the nuclei of cells at the invasive edge of these tumors (Mizunuma et al, 
2003). The very significant association between LMO4 and LDB1 abundance, which 
would not be obligate despite their interaction in cells, prompted the hypothesis that 
LMO4 and LDB1 were protected by SSBPs from ubiquitylation and subsequent 
proteasomal destruction in head and neck carcinoma analogous to that mechanism 
reported in erythroid cells (Xu et al., 2007).  The expression levels of LMO4 and LDB1 
in oral cavity tumors were evaluated first to confirm the published expression results, and 
then extended to include SSBP2 and SSBP3. The expression levels of all four proteins 
were then evaluated in primary oropharyngeal tumors and lymph node metastases. 
SSBP2 expression was further analyzed using head and neck carcinoma tissue 
microarrays (TMAs).  Finally, LMO4, LDB1, and SSBP protein levels were measured in 
human oral cavity carcinoma cell lines.   
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Figure 3.1 Immunolocalization of LMO4, LDB1, SSBP2, and SSBP3 in 
human oral cavity carcinoma. (A) LMO4, (B) LDB1, (C) SSBP2, and (D) 
SSBP3 protein expression was enriched at the invasive edge (thick arrows) 
compared to more central regions of tumor (thin arrows).    	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Immunolocalization of LMO4, LDB1, SSBP2, and SSBP3 in oral cavity carcinoma 
 Immunohistochemical analysis was carried out on sections of paraffin-embedded 
blocks from three males with squamous cell carcinoma of the oral cavity. Patients were 
between 55-58 years of age, were long-time smokers, and reported alcohol consumption 
that ranged from occasional to frequent. Clinical stage ranged from I-IV and tumors were 
moderately to well differentiated. All tumors were p16INK4A negative and two had 
metastasized to cervical lymph nodes. Confirming published data (Mizunuma et al., 
2003), LMO4 and LDB1 were expressed in the nuclei of carcinoma cells, with expression 
enriched in cells at the invasive edge (thick black arrows, Figure 3.1A and B). SSBP2 and 
SSBP3 also localized to nuclei of oral cavity carcinoma cells, and their expression was 
likewise increased in cells at tumor edge (thick black arrows, Figure 3.1C and D).  
  
Immunolocalization of LMO4, LDB1, and SSBPs in oropharynx carcinoma 
Primary oropharynx tumors 
The analysis was expanded to HPV-positive squamous cell carcinomas of the 
oropharynx (n = 7). Samples included six males and one female aged 44-75. In contrast 
to the first group, five of the seven had never smoked, with alcohol consumption ranging 
from occasional to frequent. All tumors were p16INK4A-positive, a surrogate for HPV 
positivity (Zhang et al., 1999), and three of the seven tumors had metastasized to cervical 
lymph nodes, which were available for study (See: Metastatic lymph nodes). Importantly, 
immunohistochemical staining for LMO4, LDB1, SSBP2 and SSBP3 (Figure 3.2A, C, E, 
and G) in these oropharyngeal carcinomas was identical to what was observed for the oral 
cavity carcinomas (Figure 3.1A, B, C, D).  All four proteins localized to nuclei and were 
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Figure 3.2 Immunolocalization of LMO4, LDB1, SSBP2, and 
SSBP3 in human oropharyngeal carcinoma and regional 
lymph nodes (LN). (A) LMO4, (C) LDB1, (E) SSBP2, and (G) 
SSBP3 were each increased at the invasive edge (thick arrows) 
compared to more central regions of tumor (thin arrows). (B) 
LMO4, (D) LDB1, (F) SSBP2, and (H) SSBP3 were detectable in 
regional lymph nodes for all four carcinomas in which paired 
samples were available and exhibited a similar distribution as in 
the primary tumor. 	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increased in abundance in cells at the invasive edge, indicating a shared function of these 
proteins in invasiveness despite the very different pathogenetic mechanisms underlying 
these carcinomas of the head and neck.   
 
Metastatic lymph nodes 
To assess their involvement in metastasis, paired lymph nodes and tumors (n = 3) 
were evaluated for expression of LMO4, LDB1, SSBP2, and SSBP3. Mirroring the 
expression pattern in primary tumors, each of these proteins were expressed in lymph 
nodes involved by tumor, with their intracellular location restricted to the cell nucleus 
(Figure 3.2B, D, F, and ET AL). For all three pairs of patient samples, the abundance of 
LMO4, LDB1, SSBP2 and SSBP3 was the same or higher in lymph nodes than in 
primary tumors, indicating that tumor cells attaining regional lymph nodes maintained if 
not increased their expression of LMO4, LDB1, SSBP2, and SSBP3. This lends support 
to the notion that these proteins regulate a genetic program involved in invasiveness in 
this tumor type.  
 
Immunolocalization of SSBP2 in human head and neck carcinoma arrays 
 LMO4 overexpression in oral cavity carcinomas has also been reported to be 
associated with reduced tumor cell differentiation (Mizunuma et al., 2003; Kwong, et al., 
2011).  In order to explore whether other members of a predicted LMO4, LDB1, and 
SSBP-containing complex had a similar relationship with tumor cell differentiation, 
SSBP2 expression was analyzed in two human HNSCC tissue microarrays. The 
combined TMAs provided 96 tumor samples from mixed types of HNSCC, with the 
majority from oral cavity or oropharyngeal subtypes.  Approximately 50% of poorly  
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Figure 3.3 Percentage moderate/strong SSBP2 staining compared to 
differentiation.  The percentages of moderate to strong SSBP2 staining present in 
various stages of head and neck tumor differentiation.  Head and neck tumor samples 
were evaluated for SSBP2 expression with immunohistochemistry analysis.   50% of 
poorly differentiated tumors had moderate/strong SSBP2 staining. Moderately-
differentiated and well-differentiated tumors showed a decrease (38% and 22%, 
respectively) in moderate to strong SSBP2 staining (R2 = 0.98). 	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differentiated tumors had moderate-strong SSBP2 staining (Figure 3.3).  Percentages of 
moderate-strong SSBP2 staining decreased in moderately differentiated tumors (37%) 
and poorly differentiated tumors (22%).  Importantly, SSBP2 expression was inversely 
correlated with tumor differentiation in the TMA samples, which corresponds with the 
published LMO4-tumor differentiation relationship, and provides support that both 
proteins may be influencing the same tumor cell properties in HNSCC.   
 
Expression of LMO4, LDB1, and SSBPs in oral cavity carcinoma cell lines 
 After analyzing LMO4, LDB1, and SSBP expression in oral cavity and 
oropharyngeal tumors and lymph nodes, their abundance was measured in a panel of 
human oral head and neck carcinoma cell lines. Applying highly quantitative immunoblot 
analysis to ten established oral cavity carcinoma lines, and the relative abundance of 
LMO4, LDB1, and SSBPs was determined. As predicted by semi-quantitative 
immunohistochemical analysis (Figure 3.1, 3.2), LMO4 and LDB1 showed a highly 
significant correlation in their protein levels (R2 = 0.90, P < 0.0001) (Figure 3.4A). 
Highly significant correlations were discovered between SSBP and LDB1 abundance 
(SSBP2 vs. LDB1, R2 = 0.95, P < 0.0001; SSBP3 vs. LDB1, R2 = 0.94, P < 0.0001)  
(Figure 3.4B) and between SSBP and LMO4 abundance (SSBP2 vs. LMO4, R2 = 0.80, P 
< 0.0005; SSBP3 vs. LMO4, R2 = 0.84, P < 0.0002) (Figure 3.4C). Taken together with 
published data from transfected cells showing SSBPs protect LDB1 and LMO2 and 
LMO4 from proteasomal destruction (Xu et al., 2007), these results are compatible with 
SSBPs coordinately regulating turnover of LMO4 and LDB1 in this tumor type.  
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Figure 3.4 Relative expressions of LMO4, LDB1, SSBP2, and SSBP3 in panel of 10 
human oral cavity squamous cell carcinoma lines. The relative abundance of LMO4, 
LDB1, SSBP2, and SSBP3 were found to be significantly interrelated using immunoblot 
analysis.  (A) LMO4 and LDB1 abundance were significantly correlated (R2 = 0.90, P < 
0.0001, n = 10). (B) SSBP and LDB1 abundance were significantly correlated (black 
triangles SSBP2: R2 = 0.95, P < 0.0001, n = 10; white triangles SSBP3: R2 = 0.94, P < 
0.0001, n = 10). (C) SSBP and LMO4 abundance were significantly correlated (black 
triangles SSBP2: R2 = 0.80, P < 0.0005, n = 10; white triangles SSBP3: R2 = 0.84, P 
<0.0002, n = 10).  	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Conclusions 
The expression analyses in this chapter resulted in many important findings.  
First, the published results of LMO4 and LDB1 having concordant upregulation in oral 
cavity squamous cell carcinomas and localization to the nuclei of cells at the invasive 
edge of these tumors were confirmed.  Second, SSBP2 and SSBP3 were also found to 
have concordant expression and co-localization with LMO4 and LDB1 in both oral cavity 
tumors and oropharyngeal tumors, and all four proteins of interest had maintained or 
increased expression in lymph node metastases.  Third, SSBP2 was found inversely 
correlated with tumor differentiation, similar to reported correlation between LMO4 and 
reduced tumor cell differentiation.  Finally, the concordant expression of LMO4, LDB1, 
and SSBPs was also present across a panel of human oral cavity carcinoma cell lines.  
Together, these findings support the hypothesis that LMO4, LDB1, and SSBPs are 
important for the progression of head and neck carcinoma.  
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CHAPTER IV 
 
EFFECTS OF LDB1 GENE-TARGETED HUMAN OCC CELLS 
 
Introduction 
After expression analyses were completed for LMO4, LDB1, and SSBPs (Chapter 
III) and correlations between the protein levels and tumor phenotypes were observed, loss 
of function studies were executed to measure direct biological and mechanistic effects of 
the proposed complex.  A brief invasion analysis was conducted to determine whether the 
abundance of these proteins correlated with cellular invasiveness. In general, the invasive 
potential of the cell lines measured correlated with levels of LMO4, LDB1, and SSBPs 
(data not shown). Indeed, the most invasive cell line, VU-SCC-1729, exhibited the 
highest levels of LMO4, LDB1, SSBP2, and SSBP3 and was selected for use in loss-of-
function studies.  LDB1, which serves as an adapter protein that simultaneously contacts 
LMO proteins and SSBPs through their LIM interaction domain and LDB1/Chip 
conserved domain, respectively, was selected for targeting based on the hypothesis that a 
loss of this protein would best disrupt the putative DNA-binding complex(es) containing 
LMO4, LDB1, and SSBPs (Chapter 1, Figure 1.2).  
 
CRISPR/cas9 mediated deletion of LDB1 
CRIPSR/cas9-mediated gene targeting was used to disrupt both exons 1 and 2 of 
LDB1 to maximize the chance of successful reduction in the encoded protein. Whereas 
targeting of exon 1 resulted in only a partial reduction in LDB1 expression, targeting of 
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Figure 4.1 Reduced LDB1 expression in VU-SCC-1729 
cells decreases LMO4 abundance.  LDB1 and, to a lesser 
extent, LMO4 protein abundance were reduced in VU-SCC-
1729 cells in which the LDB1 levels were reduced by 
CRISPR-cas9-mediated deletion (VU-1729 Exon 2: clone 2; 
clone 6; clone 7) but not in cells in which gene targeting was 
not successful (VU-1729 Exon 1: clone 2; clone 5; clone 6).  	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exon 2 resulted in complete loss of expression (Figure 4.1). The reduction in LDB1 
protein levels in exon 2-targeted cells was also associated with significant reduction in 
LMO4 expression (Figure 4.1) as predicted by previous studies (Xu et al., 2007).   
 
Loss of LDB1 reduces proliferation of OCC cells in vitro 
 The developed cell lines with successful loss of LDB1 (and as a result, reduced 
LMO4) were used to test whether reduction in LDB1 and LMO4 had an effect on cell 
proliferation or viability. A significant and progressive decrease in the number of LDB1 
knockout cells (VU-1729-2:7) adherent to tissue culture plastic compared to the parental 
line was detected beginning on day 2 without a change in cellular viability (Figure 4.2) (P 
= 0.053), implicating LDB1 and LMO4 in tumor cell proliferation.  
 
Loss of LDB1 reduces invasion of OCC cells through matrigel 
To investigate whether these proteins had some role in invasion, VU-SCC-1729 
LDB1 knockout and parental cell lines were evaluated for their ability to traverse a layer 
of basement membrane in Boyden chambers in vitro. Compared to both the parental line 
and the vector control line (VU-SCC-1729+), the LDB1 knockout line VU-1729-2:7 was 
much less able to penetrate Matrigel (P = 0.0011 and P = 0.0057, respectively). In accord 
with expression data, the invasiveness of the exon 1-targeted line VU-1729-1:2 was 
significantly reduced compared to the parental line (P = 0.0114) but less so compared to 
the exon 2-targeted line (Figure 4.3). Thus, reduction of LDB1 and LMO4 protein 
abundance and, by inference, an LDB1/LMO4/SSBP transcriptional complex, decreased 
cellular invasiveness in reconstituted basement membrane. 
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Figure 4.2 Loss of LDB1 expression in VU-SCC-1729 cells 
reduced growth in vitro. Cells with a reduction in LDB1 protein 
abundance (VU-1729-2:7, red line) also had decreased growth rate in 
vitro compared to VU-SCC-1729 cells (blue line) beginning on Day 2 
(P = 0.053).  	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Figure 4.3 Loss of LDB1 expression in VU-SCC-1729 cells significantly 
reduces cellular invasiveness in 2-D Matrigel invasion assay.  Invasion 
through a layer of reconstituted basement membrane (Matrigel) was 
compared for VU-SCC-1729 cells (VU-1729-P), a knockout vector control 
(+), a cell clone with only modest LDB1 knockdown (VU-1729-1:2), and 
cells in which LDB1 protein expression was effectively eliminated (VU-
1729-2:7). 	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Loss of LDB1 reduces OCCs invasion through organotypic co-cultures  
 To evaluate invasiveness in a more physiologic context, parental (VU-SCC-1729) 
and LDB1 knockout (VU-1729-2:7) cell lines were tested in an organotypic 
reconstruction permitting two-dimensional visualization of the oral cavity carcinoma 
cells invasive into a surrounding cells in addition to basement membrane. Tumor cells 
were co-cultured on a a mixture of embryonic fibroblasts, collagen, and Matrigel as 
previously described (Andl et al., 2010). For both lines cells emanating from the 
epithelial layer and invading the fibroblastic layer as individual cells were noted (Figure 
4.4, thick arrows) characteristic of epithelial-mesenchymal transition (EMT) in which 
cells lose their affinity for and attachment to each other and gain invasive functions. In 
the parental line, in addition, clusters of cells still adherent to each other (Figure 4.4, thin 
arrows) were seen invading the fibroblastic layer, a distinct form of invasiveness termed 
collective cell migration (or invasion). Importantly, the number of these clusters was very 
significantly reduced in the LDB1 knockdown cell line VU-1729-2:7 compared to 
parental cells (P < 0.0001) (Figure 4.4). Together, data from two different assays of 
tumor cell invasiveness showed that depletion of LDB1 and LMO4 significantly reduced 
that function and suggest that invasion of oral cavity carcinoma cells through epithelium 
and extracellular matrix is critically dependent on LDB1 protein abundance.  	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Figure 4.4 Loss of LDB1 expression in VU-SCC-1729 cells significantly 
reduces cellular invasiveness in 3-D co-culture assay.  Invasion through 
a fibroblast monolayer and into extracellular matrix was compared for 
parental and VU-1729-2:7 cells. The highly invasive cell line VU-1729-P 
showed significant penetration of the collagen/fibroblast matrix by clusters 
of cells (thin arrows) and individual cells (thick arrows). LDB1 knockout 
cells showed significantly reduced invasion, with only a few individual 
cells invading noted (thick arrows) and no larger collections of cells. *, P < 
0.01; ***, P < 0.0001.  	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Tumor xenografts of LDB1 gene-targeted human OCC cells 
 To better evaluate the function of the LIM-only and LIM domain interacting 
protein in head and neck carcinoma cells in vivo, limiting numbers of parental and LDB1 
knockout (VU-1729-2:7) cells were injected into nude mice and tumor volumes measured 
over a period of 23 days. Although tumor volumes did not differ significantly over the 
first five days (P = 0.766), tumors derived from LDB1 knockout cells were significantly 
different on Day 10 (P = 0.002) and were progressively smaller than those derived from 
parental cells on Day 13 (P = 0.00096), Day 20 (P = 0.0000194), and Day 23 (P = 
0.0000345) (Figure 4.5A).  Thus, LDB1 and LMO4 protein abundance are also critical 
for tumor growth in vivo. 
To determine whether this difference in tumor growth affected apoptosis, 
proliferation, or both, tumors were harvested on Day 23, sectioned, and stained with 
antibodies to caspase-3 and PCNA, respectively. Tumors derived from LDB1 KO cells 
did not stain differently from parental tumors in expression of the apoptotic marker 
caspase-3 (P = 0.2406) (Figure 4.5B) but did exhibit significantly lower labeling with 
antibody to the proliferation marker PCNA (Figure 4.5C). This was entirely consistent 
with the reduced proliferation of LDB1-deficient VU-SCC-1729 cells in vitro (Figures 
4.3 and 4.4).  
 
Effect of LDB1 deletion on tumor vascularization 
In addition to being smaller in size, tumors derived from the LDB1 KO cells 
appeared less vascularized compared to those derived parental VU-SCC-1729 cells (see 
Figure 4.5A insert).   
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Figure	   4.5	   (opposite	   page)	   Loss of LDB1 expression in VU-SCC-1729 cells 
significantly reduces tumor growth in nude mice. 	   (A) Tumor growth in nude 
mouse xenografts was compared in VU-SCC-1729 cells and cells in which LDB1 
protein expression was effectively eliminated (LDB1 KO). Tumor volumes were 
compared beginning on Day 5 (P = 0.766). A difference in tumor size was detected on 
Day 10 (P = 0.002), with this difference becoming progressively greater from Day 13 
(P = 0.00096), to Day 20 (P = 0.0000194), to Day 23 (P = 0.0000345). (B) Caspase-3 
staining for apoptosis was not significantly different in LDB1 KO vs. parental tumors 
(P = 0.2406). (C) PCNA staining for proliferation was significantly reduced in LDB1 
KO tumors compared to tumors derived from parental VU-SCC-1729 cells (P = 
0.00028).	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To evaluate this observation, the two sets of tumors were stained with an antibody 
for an endothelial cell marker, Von Willebrand Factor (vWF). Indeed, LDB1 KO tumors 
exhibited significantly decreased vWF staining compared to parental tumors (P = 
0.00196) (Figure 4.6). Collectively, the results of these xenotransplantation assays 
demonstrated that loss of LDB1 protein, and presumably the transcriptional complex(es) 
to which it contributed in association with LMO4 and SSBPs, reduced the growth and 
vascularization of tumors derived from human head and neck carcinoma cells. 
 
RNA-seq analysis of LDB1 gene-targeted human OCC cells 
In order to begin an investigation on what genetic targets were altered by the loss 
of LDB1, and therefore potentially regulated by a proposed complex containing LMO4, 
LDB1, and SSBPs, RNA-seq analysis was carried out on LDB1 knockout (VU-1729-2:7) 
and control (VU-SCC-1729-P) cell lines. These RNAs were ranked according to the level 
of significance of the difference in their abundance between knockout and parental lines 
and then grouped according to the cellular processes to which they potentially 
contributed.  The iPathway analysis found 135 RNAs that were significantly changed 
with a threshold set of P < 0.05 and log fold change of 2.  The differentially expressed 
genes discovered in the screen were found to contribute to a number of processes 
important in the promotion or spread of cancer including: transcriptional misregulation in 
cancer, ECM-receptor interaction, TGF-ß signaling pathway, PI3K-Akt signaling 
pathway, pathways in cancer (Figure 4.7).   	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Figure 4.6 Loss of LDB1 expression in VU-SCC-1729 cells 
significantly reduces angiogenesis in nude mice. Endothelial 
cells in nude mice xenografts were compared for VU-SC-1729 
(parental) and VU-1729-2:7 cells in which LDB1 protein 
expression was effectively eliminated (LDB1 KO). Endothelial 
cells are stained with Von Willebrand Factor (VWF) (green 
immunofluorescence) and nuclei are stained with DAPI (blue 
immunofluorescence).  Angiogenesis was significantly decreased 
in LDB1 KO tumors (p = 0.00196). 	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Conclusions 
 Loss of function studies targeting LDB1 in the invasive oral carcinoma cell line 
resulted in several important findings regarding the biological impact of a proposed 
complex containing LMO4, LDB1, and SSBPs.  First, as predicted, a loss of LDB1 also 
reduced LMO4 protein levels.  These oral cavity cells with a loss of LDB1, and 
subsequent LMO4 reduction, retained cell viability but experienced a decreased 
proliferative advantage.  The same cells were less invasive in two different in vitro 
invasion assays. Xenografts comparing control cells with LDB1 reduced oral cavity cells 
showed loss of LDB1 resulted in a growth and vascularization disadvantage.  These 
biological results, in combination with changes in RNA-expression in response to a loss 
of LDB1, highlight the direct role of LDB1, LMO4, and likely SSBPs in a variety of 
pathways important for the progression of HNSCC.   	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Figure 4.7 Significantly impacted pathways identified with iPathway 
Guide for differentially expressed genes in VU-SCC-1729 vs. VU-
1729-2:7 cells.  Numbers represent percentage of genes in each category 
that were differentially expressed using a threshold of 0.05 for statistical 
significance and 2 for absolute log expression change.  P-values 
corresponding to the pathways are as follows: ECM-receptor interaction 
(P = 0.0000527), pathways in cancer (P = 0.001), TGF-beta signaling 
pathway (P = 0.002), transcriptional misregulation in cancer (P = 0.002), 
PI3K-Akt signaling pathway (P = 0.003). 
 
	   66	  
CHAPTER V 
 
SSBP2 AND LDB1 DNA-OCCUPANCY IN HUMAN OCC CELLS 
 
Introduction 
 In order to determine whether LDB1 and SSBP2 may contribute to a common 
DNA-binding complex that regulated transcriptional targets involved in proliferation, 
invasiveness, and angiogenesis, genome-wide ChIP-exo was performed on VU-SCC-
1729-P cells.  This experiment, which by design allows for the generation of a next 
generation DNA sequence library containing all locations that were bound by the 
antibody used, allowed for genome-wide analysis of DNA occupancy of both LDB1 and 
SSBP2 with base-pair resolution.  There were many regions that contained signals from 
both LDB1 and SSBP2, and those peaks were investigated further.  There were also two 
distinct types of peaks that were isolated by this technique, the first was classified as 
‘clustered peaks’ and the second was classified as ‘distinct peaks’.  Both peak classes 
contained overlapping signals from LDB1 and SSBP2 antibodies, and were further 
validated and investigated through conventional ChIP analysis.  
 
Genome-wide ChIP-exo of SSBP2 and LDB1 in OCC cells 
Clustered peaks 
 The first of the two peak classes that was isolated through the sequencing analysis 
pipeline was termed ‘clustered’.  Clustered regions contained both large numbers of 
LDB1 and SSBP2 reads and had multiple single peaks directly proximal to one another 
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Figure 5.1  Clustered peak in the MIR3687 promoter.  Shown is ~4 Kb window 
comparing LDB1 (top track) and SSBP2 (middle track) ChIP-exo results in 
relation to the Hg19 reference genome (bottom track). Signals derived from the 
forward strand (blue) and from the reverse strand (red) are clustered one after 
another in approximately 8 clustered peaks upstream of MIR3687.   	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 (Figure 5.1).  Graphically, these clusters appeared to be stretches of forward and reverse 
reads that spanned several hundred base pairs. In many cases, the clustered peaks were 
within the boundaries of potential regulatory regions of genes.  A large clustered peak is 
shown upstream of two miRNAs, MIR3687 and MIR3648, surrounded by smaller orphan 
reads or non-called peaks (figure 5.1).  A second large clustered peak was identified both 
upstream of CDC27, and within an exon of CDC27 (data not shown).  These three 
clustered peaks (MIR3687, CDC27, CDC27 exon) were tested in conventional ChIP 
assays to validate LDB1 and SSBP2 occupancy.  Importantly, none of the clustered peaks 
showed increased occupancy relative to normal IgG (figure 5.3) and were eliminated 
from further analysis. 
 
Distinct peaks 
 The second of the two peak classes that was isolated through the sequencing 
analysis pipeline was termed ‘distinct’.  Like clustered peaks, distinct peaks contained 
large numbers of both LDB1 and SSBP2 reads, however they did not have multiple runs 
of forward and reverse reads directly proximal to one another (Figure 5.2).  Graphically, 
these distinct peaks were defining a much smaller region (~150 base pairs) and were 
within the boundaries of potential regulatory regions of genes.  A large distinct peak is 
shown upstream of CDH11 (figure 5.2).  The distinct peak in the promoter of CDH11, 
and a control region within an exon of CDH11, were tested in conventional ChIP assays 
to validate the distinct peak.  The distinct peak upstream of the CDH11 TSS had 
increased occupancy compared to both normal IgG and to the control exon region (figure 
5.3).  The analysis continued with only data derived from distinct peaks.   
	   69	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2  Distinct peak in the CDH11 promoter.  Shown is ~7.5 Kb window 
comparing LDB1 (top track) and SSBP2 (middle track) ChIP-exo results in 
relation to the Hg19 reference genome (bottom track). Signals derived from the 
forward strand (blue) and from the reverse strand (red) are in one distinct location 
upstream from the CDH11 transcriptional start site.  	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Figure 5.3 Validation of clustered and distinct peaks.   
LDB1 and SSBP2 ChIP-exo signals were validated using 
conventional ChIP analysis followed by qPCR.  Probes 
were designed to validate clustered peak in MIR3687 
promoter and distinct peak in CDH11 promoter regions.  
CDC27, CDC27 exon, and CDH11 exon probes were 
designed as negative controls.    	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Validated target genes 
CDH11 promoter 
 CADHERIN-11 (CDH11), a member of the cadherin superfamily whose normal 
role is maintaining cell-cell adhesions in osteoblastic differentiation, has also been found 
to be overexpressed in 15% of breast cancers and essential for tumor progression in 
others (Assefnia et al., 2014). Although the importance of CDH11 in head and neck 
carcinoma is unknown, the link to general tumor progression and importance in cell-cell 
adhesion make it an interesting potential target for a LDB1, SSBP2-containing complex 
in this disease.   
A distinct ChIP-exo peak was found in the promoter region of CDH11, located 
approximately 2.5 kilobases upstream of the TSS.  Forward (blue) and reverse (red) reads 
from LDB1 and SSBP2 ChIP-exo sequencing results were graphed in the integrated 
genomics viewer (IGV, Broad Institute) (Figure 5.4A).  The same viewing window was 
opened using UCSC ENCODE genome browser (Figure 5.4B). Viewable within the 
ENCODE window are two tracks, layered activating marks and DNA hypersensitivity 
regions, which can be seen all along the promoter region of CDH11.  Although the 
signals for activating marks are decreasing as they approach the region occupied by 
LDB1 and SSBP2, the DNA hypersensitivity marks remain present there, indicating that 
the peak is located in an open and active transcriptional region.  A third track open within 
the ENCODE genome browser is the transcription factor ChIP-seq results, which 
graphically shows where different transcription factors have been found to bind (Figure 
5.4B).  No known transcription factors within the ENCODE ChIP-seq database appear  
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Figure 5.4 Distinct peak upstream of CDH11 promoter aligned with UCSC 
Encode genome browser.  Window displayed is chr16:65,155,397-65,159,185.  (A) 
LDB1 (top track) and SSBP2 (middle track) ChIP-exo results in relation to the Hg19 
reference genome (bottom track). Signals derived from the forward strand (blue) and 
from the reverse strand (red) are in one distinct location upstream from the CDH11 
transcriptional start site. (B) Encode browser tracks from Top to Bottom: UCSC 
genes, layered H3K27ac activating marks, DNase hypersensitivity regions, and 
transcription factor ChIP-seq data.   	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directly in the peak region, however, there are many transcription factor binding locations 
proximal to the peak.   
 
CKAP2L promoter 
 Cytoskeleton Associated Protein 2-Like (CKAP2L) is a mitotic spindle protein 
critical for neural stem and progenitor cells.  CKAP2L has been linked to cell cycle 
progression in neural progenitor cells and deletions affecting CKAP2L have been 
associated with various cancers including head and neck carcinoma (Klivmov, 2013). 
These links made it an interesting potential target for a LDB1 and SSBP2-containing 
transcriptional complex in this disease. 
The distinct peak found in the promoter region of CKAP2L was located 
approximately 4 kilobases upstream of the TSS.  Forward (blue) and reverse (red) reads 
from LDB1 and SSBP2 ChIP-exo sequencing results were graphed in the IGV (Figure 
5.5A).  The same viewing window was opened using UCSC ENCODE genome browser 
(Figure 23B). For this promoter, the ENCODE track marking layered activating marks 
(H3K27ac) has a small signal peak proximal to the LDB1 and SSBP2 peak.  The track 
showing the DNA hypersensitivity regions is offset slightly, although still very proximal 
to the corresponding ChIP-exo peak (Figure 5.5B). The third track open within the 
ENCODE genome browser indicating known transcription factors within the ENCODE 
ChIP-seq database appear directly in the peak region (Figure 5.5B). Together, these three 
tracks indicate likelihood that the LDB1/SSBP2 ChIP-exo peak is located in an open and 
active transcriptional region.   
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Figure 5.5 Distinct peak upstream of CKAP2L promoter aligned with UCSC 
Encode genome browser.  Window displayed is chr2:113,521,377-113,526,475.  (A) 
LDB1 (top track) and SSBP2 (middle track) ChIP-exo results in relation to the Hg19 
reference genome (bottom track). Signals derived from the forward strand (blue) and 
from the reverse strand (red) are in one distinct location upstream from the CKAP2L 
transcriptional start site. (B) Encode browser tracks from Top to Bottom: UCSC 
genes, layered H3K27ac activating marks, DNase hypersensitivity regions, and 
transcription factor ChIP-seq data.   	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HMGA2 intron 
 High Mobility Group AT-Hook 2 (HMGA2) is an architectural factor and 
essential component of the enhancesome, which is normally expressed only in early 
development.  The expression of HMGA2 has been associated with a variety of poor-
prognosis tumors, and has been implicated to promote breast cancer metastasis and 
recurrence of squamous cell carcinoma, although the mechanism is unknown (Boo et al., 
2005).  These associations made it an interesting potential target for a LDB1 and SSBP2-
containing transcriptional complex in this disease. 
The distinct peak for HMGA2 differed from the first two promoter peaks in that it 
was found in the second intron.  Forward (blue) and reverse (red) reads from LDB1 and 
SSBP2 ChIP-exo sequencing results were graphed in the IGV (Figure 5.6A).  The same 
viewing window was opened using UCSC ENCODE genome browser (Figure 5.6B). For 
this intronic peak, the first ENCODE track marking layered activating marks (H3K27ac) 
has a small signal peak directly in line with the LDB1 and SSBP2 peak.  The second 
track showing the DNA hypersensitivity regions is also directly in line with the ChIP-exo 
peak (Figure 5.6B). The third track depicting the transcription factor ChIP-seq database 
results shows several binding regions directly in line with peak region (Figure 5.6B). 
Together, these three tracks indicate a strong likelihood that the LDB1/SSBP2 ChIP-exo 
peak is located in an open and active transcriptional region.   
  
	   76	  
 
 
  
Figure 5.6 Distinct peak upstream of HMGA2 intron aligned with UCSC 
Encode genome browser.  Window displayed is chr12:66,271,330-66,274,135.  
(A) LDB1 (top track) and SSBP2 (middle track) ChIP-exo results in relation to the 
Hg19 reference genome (bottom track). Signals derived from the forward strand 
(blue) and from the reverse strand (red) are in one distinct location inside the 
HMGA2 second intron. (B) Encode browser tracks from Top to Bottom: UCSC 
genes, layered H3K27ac activating marks, DNase hypersensitivity regions, and 
transcription factor ChIP-seq data.   	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Target gene occupancy reduced in LDB1 KO cells 
 Several factors made the CDH11-promoter, CKAP2L-promoter and HMGA2-
intron promising target regions for validation of the ChIP-exo experiments.  First, all 
three distinct peaks were co-occupied by LDB1 and SSBP2 (Figures 5.4A, 5.5A, 5.6A).  
Second, all three distinct peaks were in or proximal to regions of activating acetylation 
marks and DNA hypersensitivity when compared with the UCSC ENCODE genome 
browser  (Figures 5.4B, 5.5B, 5.6B).  Third, all three distinct peaks were in line or 
proximal with at least one reported transcription factor binding site based ChIP-seq data 
in a variety of cell lines as reported in the UCSC ENCODE genome browser (Figures 
5.4B, 5.5B, 5.6B). Together, these factors contributed support for the existence of a 
multiprotein complex containing both LDB1 and SSBP2 that can bind to these various 
regulatory regions.  The conventional ChIP assay was carried out in the invasive head 
and neck carcinoma cell line VU-SCC-1729 cells, where endogenous levels for LDB1 
and SSBP2 levels were previously found to be high (Chapter III, figure 3.4).  As 
predicted, CDH11-promoter, CKAP2L-promoter, and HMGA2-intron were all found to 
have increased LDB1 and SSBP2 occupancy compared to normal IgG in VU-SCC-1729-
P cells (Figure 5.7), ultimately validating the ChIP-exo and sequencing analysis pipeline 
results. 
Next, the occupancy of LDB1 and SSBP2 at the CDH11 promoter, CKAP2L 
promoter, and HMGA2-intron was evaluated in VU-1729-LDB1 KO cells (figure 5.7).  
The loss of LDB1 in the invasive head and neck cell line did, in fact, reduce the 
occupancy of both LDB1 and SSBP2 in all three of the target regulatory regions.   
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Figure 5.7 LDB1 and SSBP2 occupancy is reduced in 
VU-1729-LDB1 KO cells.  Three distinct peaks 
discovered in the ChIP-exo analysis (CDH11 promoter, 
CKAP2L promoter, HMGA2 intron) were validated in 
conventional ChIP analysis using VU-1729-P cells for 
LDB1 (blue bars) and SSBP2 (green bars).  VU-1729-
LDB1 KO cells also evaluated for occupancy at the 
same regions.  Both LDB1 (red bars) and SSBP2 (purple 
bars) had reduced occupancy in the LDB1 KO cells 
compared to the parental cells.   	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These results reinforce the likelihood of LDB1 and SSBP2 participating in a common 
DNA-binding complex in head and neck carcinoma cells. 
 
Conclusions 
 Genome-wide ChIP-exo analysis of LDB1 and SSBP2 occupancy in the invasive 
head and neck carcinoma line VU-SCC-1729 had several important findings.  LDB1 and 
SSBP2 were found to co-occupy two subtypes of peaks. Although clustered peaks looked 
promising due to the large number of total reads in the region and for the pattern of 
forward and reverse reads in both LDB1 and SSBP2 assays, they were unable to be 
validated in conventional ChIP analysis.  This lead to the conclusion that clustered peaks 
are artificially enriched background signals with no probable biological significance.  The 
co-occupancy of LDB1 and SSBP2 for three distinct target peaks was, however, validated 
with conventional ChIP analysis.  Furthermore, the occupancies of LDB1 and SSBP2 
were significantly reduced in VU-1729-LDB1 KO cells compared to VU-SCC-1729-P 
cells.  Overall, these validation results support the genome-wide ChIP-exo and 
subsequent sequencing analysis pipelines, and supported the use of those data in further 
studies for motif discovery (Chapter VI).   
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CHAPTER VI 
 
IDENTIFICATION OF SSBP2 AND LDB1 BINDING LOCI 
 
Introduction 
 One of the key methods for investigating gene regulatory regions and the 
multiprotein complexes that bind them is motif analysis.  DNA motifs are amino-acid 
sequence patterns that are widespread, non-random, and have biological significance.  
Many transcription factors regulate multiple genes by binding to a common sequence 
motif within a given gene’s regulatory regions.  The proximal promoter, a standard 
regulatory region, is located directly upstream of the transcriptional start site (TSS) of a 
gene and contain many different motifs to which factors bind to signal transcription 
initiation.   The distal promoter and intronic regions of a gene can also contain motifs that 
recruit regulatory factors. Unlike the proximal promoter elements, these regions can be 
several kilobases upstream or downstream of the TSS.  
There are many combinatorial ways that these regulatory regions and the factors 
that bind to them can alter gene expression.  Although LMO4, LDB1, and SSBPs are 
adapter that stabilize multiprotein transcriptional complexes, they themselves do not 
directly contact DNA.  Additionally, the DNA-binding components of complexes 
containing LMO4, LDB1, and SSBPs in head and neck carcinoma cells have yet to be 
determined.  In order to investigate how increased LDB1 and SSBPs (and presumably 
LMO4) in the cell are influencing a pro-oncogenic phenotype in head and neck 
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carcinoma, the DNA sequence motifs to which those proteins may be recruited to target 
genes were evaluated.  
Here within, motif analysis was used to discover patterns within the sequence in 
locations that were occupied by LDB1 and SSBP2 in the invasive head and neck 
carcinoma cell line VU-SCC-1729 as indicated by the genome-wide ChIP-exo studies 
described in Chapter V.  To discover motifs, biostatistician Yan Guo (Vanderbilt 
University, Nashville, TN) used statistical motif analyses to determine base-pair patterns 
within groups of sequences.  The newly discovered motifs were then compared to a 
database containing known transcription factor binding motifs (Jaspar families database).  
The motifs and their locations were then considered for a potential regulatory role in 
promoting a pro-oncogenic or invasive phenotype.  The motifs were also directly 
compared with changes in RNA expression when LDB1 expression is lost, and with 
validated ChIP gene targets.      
 
Motif discovery 
Promoter peak motifs 
The DNA sequences from the top 37 co-occupied, distinct promoter peaks were 
selected from the LDB1 and SSBP2 ChIP-exo results (Table 6.1).  These sequences were 
compared to one another using bio-statistical analyses to determine the top three 
significantly repeated motifs (biostatistician Yan Guo, Figure 6.1).  These three motifs 
were inputted into STAMP analysis (algorithm written by Shaun Mahony, University of 
Pittsburgh, Pittsburgh, PA), which compared each of the discovered motifs to existing 
transcription factor databases.  The results of the STAMP analysis were familial motif 
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trees that highlighted the most similar known motif with the discovered motif counterpart 
(Figure 6.1).  The discovered promoter peak motifs included well-known E-box motifs 
and a homeobox motif.  Specific transcription factors that were linked to these binding 
motifs included C2H2, MEF2A, and RUNX1 (Figure 6.1).   
 
Intronic peak motifs  
The DNA sequences from the top 33 co-occupied, distinct intronic peaks were 
selected from the LDB1 and SSBP2 ChIP-exo results (Table 6.2).  These sequences were 
compared to one another using biostatistical analyses to determine the top three 
significantly repeated motifs (biostatistician Yan Guo, Figure 6.2).  These three motifs 
were inputted into STAMP analysis, which compared each of the discovered motifs to 
existing transcription factor databases.  The results of the STAMP analysis were familial 
motif trees that highlighted the most similar known motif with the discovered motif 
counterpart (Figure 6.2).  Like the promoter peaks, the discovered intronic peak motifs 
also included well-known E-box motifs.  Homeobox motifs, however, were not 
statistically represented in the intronic peak regions.  Specific transcription factors that 
were linked to these binding motifs included FOXD1, ARNT, and RUNX1 (Figure 6.2).   
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Table 6.1 Promoter peak DNA sequences. Gene names and associated DNA 
sequences for distinct ChIP-exo peaks found in the promoter regions of listed genes. 
E-box motifs (red), homeobox motifs (blue). 	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Figure 6.1 Promoter discovered motifs. (Top) Top three discovered motifs in the list 
of promoter peaks.  (Bottom) Motif Tree comparing known transcription factor motifs 
to discovered motifs. The known transcription factors associated with the discovered 
motifs were C2H2, MEF2A, and RUNX1.    	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Combined promoter and intronic motifs 
After analyzing the promoter and intronic peak regions separately, the two lists of 
sequences were combined and re-analyzed.  The re-evaluation was used to determine if 
there were other motifs that were originally below the significant threshold due to low 
numbers of starting sequences. The combined DNA sequences from tables 1 and 2 (69 
total sequences) were analyzed together to determine the top three significantly repeated 
motifs among them (biostatistician Yan Guo, Figure 6.3).  The three discovered motifs 
were, once again, inputted into STAMP analysis and compared to a known transcription 
factor database (Jaspar Families database).  The STAMP analysis familial motif tree 
highlighted the closest similar known motif with the discovered motif counterpart (Figure 
6.3). As was reported for the both the individual promoter and intronic motif familial 
trees, E-box motifs were found (Figure 6.3).  Importantly, by combining the promoter 
and intronic peak sequence lists, the resolution to see the homeobox motifs, which were 
present in the promoter peak sequence list, was lost.  The specific transcription factors 
motifs included FOXD1, RUNX1 and C2H2 (Figure 6.3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	   86	  
 
 
 
 
 
 
Table 6.2 Intronic peak DNA sequences. Gene names and associated DNA 
sequences for distinct ChIP-exo peaks found in the intronic regions of listed genes. E-
box motifs (red), homeobox motifs (blue). 	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Figure 6.2 Intronic motifs. (Top) Top three discovered motifs in the list of intronic 
peaks.  (Bottom) Motif Tree comparing known transcription factor motifs to 
discovered motifs.  The known transcription factors associated with the discovered 
motifs were FOXD1, Arnt-Ahr, and RUNX1.  	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E-box and homeobox motifs 
 
The two well known motifs, E-box and homeobox, were found within the 
discovered motifs by comparing them to a known transcription factor database (Jaspar 
Families Database). Each sequence was then analyzed individually to determine which 
actual target gene regions contained an E-box or homeobox motif. The peak sequences 
were divided into three motif groups: a group that contained E-box motifs, a group that 
contained homeobox motifs, and a third group that contained sequences that did not have 
either an E-box or a homeobox motif called “other” (Table 6.3). The sequences within 
those groups were directly compared to the genes that had also changed in the VU-1729 
LDB1 knockout RNA-seq results (Chapter IV, Figure 4.7).  Importantly, 31% of genes 
with promoter peak regions and 32% of intronic peak regions corresponded with actual 
changes in the gene expression based on the RNA-seq analysis. Within those groups of 
genes, there were even smaller percentages of peaks that contained either an E-box or a 
homeobox motif (summarized in Table 6.3).  Although the majority of the gene peak 
regions that corresponding with gene expression changes were classified as ‘other’, the 
DNA sequences for all three validated ChIP-exo target genes contained either a 
homeobox or an E-box motif.  Specifically the CDH11 promoter, CKAP2L promoter, 
and HMGA2 intronic, were found to contain a homeobox motif, a double homeobox 
motif, and an E-box motif, respectively. (Table 6.4). 
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Figure 6.3 Promoter and intronic combined motifs. (Top) Top three discovered 
motifs in the combined list of promoter and intronic peaks.  (Bottom) Motif Tree 
comparing known transcription factor motifs to discovered motifs.  The known 
transcription factors associated with the discovered motifs were FOXD1, RUNX1, and 
C2H2.   	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Table 6.3 Top ChIP-exo peaks in promoter and intronic regions found by 
Rank Order. The top 36 promoter and 34 intronic peaks as found by Rank 
Order in ChIP-exo of VU-SCC-1729 cells were compared with changes in 
RNA expression as a result of LDB1 knockout in the same cells. Percentages 
of peak sequences containing an E-box or a homeobox that were discovered 
within promoter peaks and intronic peaks are shown comparatively for VU-
SCC-1729 cells and VU-1729-2:7 LDB1 knockout cells.  Percentages of peak 
sequences that did not contain an E-box or a homeobox motif that were 
discovered within promoter peaks and intronic peaks are also shown (other). 	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Table 6.4 Known motifs in validated target genes. Three regions co-occupied by 
LDB1 and SSBP2 that were discovered in ChIP-exo analyses and validated using 
conventional ChIP analysis were evaluated for specific transcription factor binding 
motifs.  CDH11 promoter and CKAP2L promoter regions both contained homeobox 
motifs.  HMGA2 intronic region contained a double E-box motif.  	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Conclusions 
The motif discovery and subsequent analyses were used to determine what DNA 
sequences an LDB1, SSBP2, and likely LMO4-containing complex might be binding to 
as transcriptional regulators.  These studies on promoter and intronic peaks returned two 
different well-known motifs of interest, the E-box motif and the homeobox motif.  While 
the combined analysis reduced the ability to find a statistically significant motif specific 
to promoter regulatory regions, the finding informs future analyses of this type that the 
regulatory regions should be separated during analysis in order to be able to maintain 
resolution of the potentially important targets. 
The identities of the actual DNA-binding proteins that participate in the 
multiprotein complex containing LDB1, SSBP2, and likely LMO4, requires further 
investigation, however, the presence of the known motifs provide some clues.  The 
homeobox motif and the E-box motif in the validated ChIP target genes points to the 
identity of the DNA-binding protein being either an LIM-Homeobox (LHX) or a basic 
helix-loop-helix (bHLH) transcription factor. Importantly, both LHX and bHLH proteins 
are known to bind to LIM-domain containing proteins and are reported with abilities to 
induce EMT (Natarjan et al., 2014, Yang et al., 2008).   
Finally, the overlap found between ChIP-exo peak regions and changes in RNA 
expression after a loss of LDB1 may indicate direct targets occupied by an LDB1, SSBP2 
containing complex.  Further occupancy studies will be necessary to confirm direct 
targets containing these proteins of interest.    
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CHAPTER VII 
 
DISCUSSION 
 
LMO4, LDB1, and SSBPs promote invasion of HNSCC cells by EMT or CCI  
There are many different regulatory mechanisms through which epithelial cellular 
identity and morphology can be reprogrammed, causing an otherwise healthy or normal 
cell to transform into a malignant one.  Inappropriate alterations in gene expression 
networks allow for otherwise in situ epithelial cells to acquire motile and invasive 
abilities. Genes involved in maintaining cell polarization and cell-cell adhesion (E-
CADHERIN) are downregulated or lost completely and genes that characterize an un-
polarized mesenchymal phenotype (N-CADHERIN, VIMENTIN, MMP3, MMP9) are 
upregulated (Natarajan et al., 2014; Graves et al., 2014). Regulatory gene programs have 
been implicated in two processes thought to mediate tumor cell motility, invasiveness, 
and finally metastasis: 1) epithelial-mesenchymal transition (EMT) (Natarajan et al., 
2014) and 2) collective cell migration (CCM) (Friedl et al., 2009) or collective cell 
invasion (CCI) (Etemad-Moghadam et al., 2015).  
This body of work has shown that the abundance of LIM domain protein 4 
(LMO4) and LIM domain-binding protein (LDB1) is increased in a majority of squamous 
cell carcinomas of the head and neck from multiple sites of origin and that their aberrant 
expression is caused, at least in part, by concomitant upregulation of two putative single-
stranded DNA-binding proteins, SSBP2 and SSBP3. These proteins block LDB1 and 
LMO4 ubiquitylation and proteosomal destruction and thereby reduce their turnover.  
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Increased expression of LMO4 and LDB1 in the cell is correlated with changes in oral 
squamous cell morphology and function. This work reports the direct involvement of 
LMO4, LDB1, and SSBPs in the promotion of tumor cell invasiveness.  In a recent study 
(Etemad-Moghadam et al., 2015), an intermediate phenotype between EMT and CCI 
were reported for 92 oral squamous cell carcinomas (OSCCs).  Our LDB1 knockout 
studies revealed a similar combinatory mode of invasion where both single invading cells 
and collective invading cell groups were found in the same oral squamous cell epithelial 
line.  A significant reduction in invasive abilities as a result of Ldb1 loss in oral cavity 
carcinoma cells possibly implicates LMO4, LDB1, and SSBPs involvement in regulating 
a phenotypic EMT boundary in this tumor type.     
 
A pro-oncogenic role of LMO4, LDB1, and SSBPs in HNSCC 
     The findings within this work add to a considerable literature showing that LMO 
proteins are pro-oncogenic, likely in association with LDB1, and establish in addition that 
these proteins control multiple aspects of tumor biology. The role of SSBPs in cancer, in 
contrast, has been less clear. While one study found a highly significant association 
between increased SSBP2 expression and poorer overall survival in glioblastoma (Xiao et 
al., 2012), another showed inhibition of prostate cancer cell growth by SSBP2 with 
increased epigenetic silencing of its promoter with tumor progression (Liu et al., 2008), 
more compatible with its function as a tumor suppressor. Similarly, there is a suggestion 
that SSBP2 acts as tumor suppressor in acute myeloid leukemia (Liang et al., 2005), and 
it is possible that SSBPs can act as either oncoprotein or tumor suppressor, depending on 
the context.   
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Influence of LMO4, LDB1, and SSBPs on HNSCC is independent of HPV status 
 There is considerable heterogeneity in carcinomas of the head and neck, despite 
the fact that greater than 90% of them are squamous cell carcinomas. Importantly, 
carcinomas originating in the oropharynx are often positive for a high-risk type of human 
papillomavirus (HPV), whereas oral cavity carcinomas (and other less common subtypes 
like nasopharyngeal carcinomas) are generally HPV-negative (Leemans et al., 2011; 
Marur and Forastiere, 2016). Even though HPV-positive head and neck carcinomas show 
different genetic alterations, have different epidemiologic patterns, and demonstrate 
significantly different responses to chemotherapy and irradiation (Hobbs et al., 2006), the 
fact that no difference was detected in either the frequency of overexpression or 
intratumoral localization of LMO4, LDB1, and SSBP2 and SSBP3 between oral cavity 
and oropharyngeal carcinomas suggest the effects of these proteins on tumor cell biology 
is independent of virus. More specifically, LMO4, LDB1, and SSBPs may regulate some 
fundamental features of HNSCC tumor progression or invasion regardless of how they 
arise. 
 
Potential role of LMO4, LDB1, SSBPs in head and neck cancer stem cells 
Importantly, an LMO protein, specifically LMO2, LDB1, and SSBP2 have each 
been found to be required for the emergence or persistence of hematopoietic stem cells 
during development (Yamada et al., 1998) and Ldb1 has also been shown to be required 
for survival of stem cells in intestinal epithelium (Dey-Guha, 2009). This work presents a 
regulatory role of LMO4-, LDB1-, and SSBP-containing transcriptional complex(es) in 
metastatic potential and angiogenesis, both of which have been ascribed to cancer stem 
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cells (CSCs).  A unifying hypothesis of these data, in consideration with the critical roles 
in developmental stem cells, is that LMO4-, LDB1-, and SSBP-containing transcriptional 
complex(es) affect stem cells, both malignant and normal.  A preliminary observation 
supporting this notion was that approximately 80% of 20 head and neck CSC markers 
were co-occupied by LDB1 and SSBP2 in the genome-wide ChIP-exo analysis described 
in Chapter VI.  Additionally, about 40% of those same CSC markers were changed in the 
RNA-seq analysis as a result LDB1 knockout in vitro.  CSCs have been detected in a 
range of epithelial malignancies, including squamous cell carcinomas of the head and 
neck, and may be, in fact, regulated by the proposed complex. 
 
LMO4, LDB1, SSBPs: promoters of angiogenesis in HNSCC 
A role for LMO4 and/or LDB1 in invasiveness, but not angiogenesis, was 
predicted from immunohistochemical localization of these proteins in biopsies of human 
oral cavity carcinomas (Mizunuma et al., 2003 and Kwong et al., 2011).  This work not 
only confirmed the previous findings and extended the analysis to confirm that SSBP2 
and SSBP3 also had a role in HNSCC cell invasiveness (Chapter III), but also reported 
the novel finding that the role of LMO4, LDB1, and SSBPs also include the promotion of 
angiogenesis in this tumor type (Chapter IV).  While LMO2 has been implicated in 
angiogenesis during normal development, these studies provide the first evidence of 
LMO4’s involvement in tumor angiogenesis, which has implications for the other tumor 
types in which it is also overexpressed. 
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LMO4-, LDB1-, SSBP-containing complexes require further investigation 
Although SSBP2, SSBP3, and, likely, SSBP4 can bind stretches of single-
stranded DNA and were first discovered as a result of this property (Bayarsaihan et al., 
1996), this single-stranded DNA-binding activity is entirely dispensable for its LDB1 and 
LMO protein stabilizing function. SSBP2 and SSBP3 have been shown to form 
multiprotein complexes with LDB1, LMO2, and heterodimers of basic helix-loop-helix 
transcription factors in erythroid cells and with LDB1 and LIM-homeodomain 
transcription factors in pituitary cells, respectively (Cai et al., 2008). Here within this 
body of work is evidence that in carcinomas of the head and neck, LMO4, is the critical 
member of an SSBP-containing multiprotein regulatory complex. An important question, 
however, that remains unanswered by this work is what are the identities of the sequence-
specific transcription factors that recruit the complex to DNA and of the genes occupied 
and regulated by the complexes.  
The genome-wide ChIP-exo studies (Chapter VI) began to answer this question 
by elucidating actual co-occupied gene targets of LDB1 and SSBP2, but further analysis 
including antibodies to LMO4 and to proposed DNA-binding transcription factors (likely 
bHLH or LIM-HD proteins) is required. Future studies should include ChIP-exo studies 
with antibodies of predicted and likely direct DNA binding proteins (E-box- and 
homeobox-binding transcription factors) to determine if such transcription factors co-
occupy the same regions as LDB1 and SSBP2 across the genome.  
Although bHLH and LIM-HD transcription factors have been well implicated in 
promoting EMT in epithelial cancers, there may be other types of transcription factors 
present in LMO4-, LDB1-, SSBP-containing multiprotein regulatory complexes that are 
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important for head and neck cancer.  Interestingly, the majority of the analyzed ChIP-exo 
peaks were not E-box or homeobox motifs.  Perhaps these ‘other’ motifs are, in fact, true 
targets of an LDB1, SSBP2-containing complex, however, they may not be directly 
involved in promoting the pro-oncogenic phenotype.  Further analyses of the ‘E-box, 
homeobox and other’ types of motifs, including both occupancy studies and additional 
transcription factor ChIP-exo analysis will be crucial for further classifying these separate 
types of binding sites.  Many of the unclassified ‘other’ motifs may, in fact, be novel 
findings, and upon further investigation could reveal important updates to the known 
transcription factor databases.  
 
Conclusion 
This body of work has addressed the hypothesis that LMO4, LDB1, and SSBPs 
participate in multiprotein transcriptional complexes that regulate head and neck cancer 
tumor cell biology.  Expression data and loss of function studies have helped to highlight 
several biological effects of these proteins that are critical for tumor cell progression 
including increased invasion, proliferation, lymph node metastasis, and angiogenesis.  
Importantly, this work has also started the identification of genome-wide binding patterns 
of complexes containing LDB1 and SSBP2, although further investigations on the direct 
DNA-binding transcription factors are necessary.  The relevance of LMO4, LDB1, and 
SSBPs in the maintenance of cancer stem cells, which may have wider implications 
outside of this tumor model alone, should also be further investigated. In sum, this body 
of work has contributed a better understanding of the mechanisms by which LMO4, 
LDB1, and SSBPs regulate tumor cell biology, but the important future studies suggested 
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here will be necessary to fully elucidate the functions of LMO-, LDB1-, SSBP- 
containing complex(es).  A more complete understanding of the genome-wide targets and 
the regulatory pathways they affect may aid the development of novel therapies to treat 
patients with invasive carcinomas of the head and neck.   
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